

From THE DEPARTMENT OF MEDICAL BIOCHEMISTRY AND
BIOPHYSICS

Karolinska Institutet, Stockholm, Sweden

**INDUCTION OF EPITHELIAL-MESENCHYMAL
TRANSITION (EMT) IN WOMEN´S CANCER:
PROTECTIVE ROLE OF DIFFERENTIATION
FACTORS**

Joel Johansson



**Karolinska
Institutet**

Stockholm 2015

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by E-Print AB 2015

© Joel Johansson, 2014

ISBN 978-91-7549-809-6

Induction of Epithelial-Mesenchymal Transition (EMT) in Women's cancer: Protective Role of Differentiation Factors

THESIS FOR DOCTORAL DEGREE (Ph.D.)

By

Joel Johansson

Principal Supervisor:

Docent Jonas Fuxe
Karolinska Institutet
Department of Medical biochemistry and biophysics
Division of Vascular Biology

Co-supervisor(s):

Professor Christer Betsholtz
Uppsala University
Department of Immunology, Genetics and Pathology
Division of Cancer and Vascular Biology

PhD Jill Johnson
Imperial Collage
Department of Medicine
Division of Leukocyte Biology

Opponent:

Professor M. Angela Nieto
Instituto de Neurociencias de Alicante
Department of Developmental Neurobiology

Examination Board:

Professor Urban Lendahl
Karolinska Institutet
Department of Cell and Molecular Biology
Division of Developmental and Stem Cell Biology

Professor Karin Sundfeldt
Göteborgs Universitet
Department of Clinical Sciences
Division of Obstetrics and Gynecology

Professor Lars Holmgren
Karolinska Institutet
Department of Oncology-Pathology

“The most difficult thing is to know what we do know, and what we do not know”

Tertium Organum, 1920, P. D. Ouspensky

ABSTRACT

Metastatic spread of cancer cells to vital organs is the predominant cause of death among women suffering from breast and ovarian cancer, and invasive cancer cells are in many cases resilient to standard drugs used in the clinic. Consequently, further understanding of the metastatic process and development of new strategies to target invasive cancer cells are needed. One process that has been closely linked to cancer cell invasion and migration is epithelial-mesenchymal transition (EMT), a developmental process, which can be reactivated during cancer progression. EMT allows carcinoma cells, with an epithelial origin, to acquire mesenchymal and migratory properties that are employed to invade the surrounding tumor tissue. The overall aim of this thesis was to investigate how EMT is induced in breast and ovarian cancer cells and to study the role of EMT in drug resistance.

Relapse of resilient cancer cells after surgery and first line of drug treatments is a major cause of death in ovarian and breast cancer. Currently, little is known about the functional properties of cancer cells that develop resistance to existing drug treatments and how they can be targeted. The aim of **study I** was to characterize the phenotypic properties of ovarian cancer cells that developed resistance to cisplatin, a chemotherapeutic drug commonly used in the clinic. We found that human SKOV-3 ovarian cancer cells that acquired resistance to cisplatin gained properties of EMT and cancer stem cells, suggesting that they were more invasive than drug-sensitive cells. Indeed, functional experiments showed that cisplatin-resistant SKOV-3 cells were more migratory in invasion assays and displayed an increased tumor initiating capacity compared to cisplatin-sensitive cells. The results from these studies link EMT to drug resistance in ovarian cancer cells, and emphasize that further understanding of EMT is needed and to be able to target EMT for therapy.

In **study II-IV** we investigated how cellular sensitivity to EMT is regulated. In particular, we focused on identifying epithelial differentiation factors that regulate EMT in breast cancer cells. We identified two transcription factors – C/EBP β and Foxp4 that were lost during breast cancer progression, which conferred cells an enhanced capacity to undergo EMT as well as to gain invasive and metastatic properties in experimental *in vitro* and *in vivo* models of breast cancer. In addition, we identified the coxsackie- and adenovirus receptor (CAR), a tight junction-based cell adhesion molecule, as a novel regulator of Akt signaling and TGF- β -induced EMT in breast cancer cells. The mechanism was traced to a role of CAR in regulating localization, stability and function of the phosphatase Pten, a potent Akt inhibitor, at tight junctions. The results from these studies indicate that the EMT process is not solely regulated by factors that drive a mesenchymal differentiation program, but also, is under tight control by epithelial differentiation factors. Loss of C/EBP β , Foxp4 and CAR may lead to increased cellular sensitivity to EMT and thereby open up the possibility that cancer cells acquire invasive and migratory properties. Based on this, we propose that novel therapies aiming to strengthen, or preserve, epithelial differentiation mechanisms in breast or ovarian cancer cells, might be useful as a type of differentiation therapy to inhibit cancer cell invasion and metastasis.

LIST OF SCIENTIFIC PAPERS

Included in the thesis:

I. My Wintzell, Lina Löfstedt, **Joel Johansson**, Pedersen AB, Jonas Fuxe, and Maria Shoshan. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. *Cancer Biol Ther.*, 2012 Dec 1;13(14):1454-62

II. **Joel Johansson** *, Tove Berg*, Ewa Kurzejamska, Meifong Pang, Vedrana Tabor, Malin Jansson, Pernilla Roswall, Kristian Pietras, Malin Sund, Piotr Religa and Jonas Fuxe, MiR-155-mediated loss of C/EBP β shifts the TGF- β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer, *Oncogene* 2013, Aug 19. doi: 10.1038/onc.2013.322

III. **Joel Johansson**, Magdalena Cichon, Laura Lambut, Vedrana Tabor, Anna Wikell, Malin Sund, Derek Radisky, Jonas Fuxe. Foxp4 controls EMT in breast cancer cells by acting as a transcriptional repressor of Snail1, *Manuscript*

IV. **Joel Johansson**, Sandra Travica, Azadeh Nilchian, Vedrana Tabor, Oskar Rosenkrantz, Malin Sund, Theresa Vincent, Jonas Fuxe. The Coxsackie- and Adenovirus Receptor Controls Akt Signaling and EMT in Breast Cancer Cells by Regulating Pten Localization and Stability at Tight Junctions, *Manuscript*

Others not included in the thesis:

V. **Joel Johansson***, Vedrana Tabor*, Anna Wikell, Sirpa Jalkanen and Jonas Fuxe, TGF- β 1-induced epithelial-mesenchymal transition induces monocyte/macrophage properties in breast cancer cells, Submitted manuscript (in press), *Frontiers in Oncology*, 2014

VI. Ewa Kurzejamska, **Joel Johansson**, Karin Jirström, Varsha Prakash, Sharan Ananthaseshan, Louis Boon, Jonas Fuxe, Piotr Religa, C/EBP β expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. *Oncogenesis*, 2014 Nov 3;3:e125. doi: 10.1038/oncsis.2014.38.

VII. Mei-Fong Pang, Anna-Maria Georgoudaki, Laura Lambut, **Joel Johansson**, Vedrana Tabor, Kazuhiro Hagikura, Yi Jin, Malin Jansson, Lars Jakobsson, Christer Betsholtz, Malin Sund, Mikael C. I. Karlsson and Jonas Fuxe, TGF- β 1-induced EMT promotes dendritic cell properties and lymphatic dissemination of breast cancer cells, Submitted manuscript (in revision). *Oncogene*, 2014

**equal contribution*

CONTENTS

1 Introduction	5
1.1 Women´s Cancer	5
1.2 Breast Cancer Progression	6
1.3 Ovarian Cancer Progression	6
1.4 Epithelial-Mesenchymal Transition.....	8
1.5 Transforming growth factor b (TGF- β).....	9
1.5.1 <i>Role of TGF-β in cancer</i>	10
1.6 Transcriptional regulation of EMT	12
1.6.1 <i>CCAAT-enhancer binding protein beta</i>	14
1.6.1 <i>Forkhead box protein p4</i>	14
1.7 Tight Junctions	15
1.7.1 <i>Coxsackie- and adenovirus receptor (CAR)</i>	15
1.8 Treatment of women´s Cancer.....	16
2 Aims of the studies	17
3. Results and Discussion	18
3.1 Paper I.....	18
3.2 Paper II	19
3.3 Paper III.....	22
3.4 Paper IV	24
4 Conclusions	26
5 Acknowledgements	28
6 References	30

LIST OF ABBREVIATIONS

Akt/PkB	Protein kinase B
AP-1	Activating Protein 1
CAR	Coxsackie- and adenovirus receptor
C/EBP β	CCAAT-enhancer binding protein beta
CLMP	CXADR-like membrane protein
CSC	Cancer Stem Cell
EGF	Epidermal Growth Factor
EMT	Epithelial-Mesenchymal Transition
EOC	Epithelial Ovarian cCncer
Foxp4	Forkhead box p4
GSK-3 β	Glykogensyntas-kinas 3 beta
HER2	Human Epidermal Growth Factor Receptor 2
HK-II	Hexokinase-II
JAM	Junctional Adhesion Molecule
MAGI-1	Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 1
MMP	Matrix Metalloproteinases
MET	Mesenchymal-Epithelial Transition
NMuMG	Namru Mouse MammaryGland
PyMT	Polyma Virus Middle-T
PR	Progesterone Receptor
Pten	Phosphatase and Tensin Homolog
PI3K	Phosphatidylinositol 3-kinase
RHOA	Ras homolog gene family, member A
RAC1	Rho family, small GTP binding protein
RAS	Rat Sarcoma Protein
SP-1	Specificity Protein 1
TAK1	TGF β activated kinase
TJ	Tight Junction
TGF β	Transforming Growth Factor Beta
TGF β R	Transforming Growth Factor Beta Receptor

I INTRODUCTION

1.1 Women's Cancer

Development of the human embryo, from one initial germ cell to a functional multi-cellular organism, is dependent on predetermined events of cellular transitions. In a controlled fashion, stem cells divide and differentiate into a number of different cell types, with the capacity to build up and maintain the physical functions of our body. This is made possible when cells follow proper genetic programs, which coordinate the course of development and the cellular response to external conditions.^{1,2} Cancer cells no longer follow proper genetic programs, and lose their ability to act in accordance with needs of the multi-cellular organism. In later stage of the cancerous disease, the potent force of transition is once more triggered and tumor cells not only divide rapidly, but change their morphology and turn invasive.^{3,4,5}

Women's cancer comprises of malignancies of the cervical, ovarian, and breast epithelia and in more rare cases the vaginal and vulvar epithelia.⁶ The incident of death of cervical cancer patients has largely been reduced in several countries due to successful screening programs. In addition, vaccine against oncogenic human papilloma virus is likely to further reduce the incidence and death caused by cervical cancer.⁷ However for breast cancer, the most common malignant disease among women in the western world, and ovarian cancer breakthroughs in finding new therapeutic alternatives are well needed.^{8,9} In particular, it would be of interest to identify and be able to target the mechanism that drives metastatic spread of breast and ovarian cancer cells.

1.2 Breast cancer progression

Breast tumor progression cannot be linked to mutations in a single pathway, and is rather a heterogeneous disease with different pathologies and molecular profiles.^{10,11} Initially, human breast tumors were categorized based on their histological features, but more recently gene expression profiling based on microarray analysis has made it possible to classify human breast tumors based on to their mRNA expression profile.^{12,13} Through mRNA profiles it is possible to divide tumors into four reproducible subtypes: luminal A, luminal B, basal and normal-like.^{12,13,14} Most subtypes of breast cancer are luminal tumors that share morphology with the inner epithelial cells facing the lumen of the mammary ducts. Luminal A tumors are positive for estrogen and the progesterone receptor (ER and PR) and negative for HER2, which makes them responsive to hormone treatment, and have a better prognosis.^{15,16} Luminal B tumors are positive for HER2, and the prognosis is poorer due to increased cell growth.¹⁷ Basal like tumors do not share the luminal morphology but instead resemble myoepithelial (or basal) cells lining the basement membrane of the mammary duct.¹⁸ Tumors with this type of morphology are more invasive and migratory.¹⁹

Usually it is not the primary breast tumor that is the cause of death in patients, but rather metastatic spread to distant sites.²⁰ Although the metastatic process is far from understood, advances with in the field have enabled us to grasp some of its complexity. Once tumor cells surpass the anti-proliferative control of tumor suppressor genes, such as p53, the retinoblastoma protein (RB) and Phosphatase and tensin homolog (Pten), and provide their own growth stimulatory factors they start to divide in an uncontrolled fashion.^{3,21,22,23,24,25} The general dogma and the explanation model of how tumors progress into an invasive state has

been that fast dividing tumor cells will accumulate more mutations that eventually allow them to acquire invasive properties. The balance between the activity of oncogenes, which may promote an invasive behavior, and tumor suppressors may play a role in dictating the invasive behavior of tumor cells.^{26,27,28} This still holds valid, but accumulating data point towards higher levels of complexity, and that intrinsic events cannot solely explain why certain breast cancer cells acquire invasive properties. Although tumor cells have lost their normal proliferative behavior, they are still growing in a context where many components come together to determine the course of progression (Figure 1).^{3,29} It is evident that both extracellular signals and intracellular events are important for the invasive behavior of tumor cells.

Mammary ducts are encapsulated by both a basement membrane and the surrounding stromal compartment containing extracellular matrix. Thus, no preexisting natural passages exists that allow mammary epithelial cells to migrate through in order to reach the blood circulation.³⁰ The basement membrane is an insoluble structure that is impermeable to large proteins, and the focal extracellular matrix is only permeable to cell movement during tissue remodeling, wound healing, inflammation and neoplasia.^{31,32,33,34} A first step of progression is therefore for tumor cells to attach to the basement membrane which is mediated by specific glycoproteins such as laminins and fibronectin, through plasma membrane receptors.^{32,35,36} When attached, tumor cells secrete hydrolytic enzymes that break up the basement membrane and start to degrade the matrix.^{37,38,39}

As tumor cells pass the boarder of what usually separates the epithelial and mesenchymal compartment they are exposed to a new microenvironment that has the potential to further modify the tumor cells.^{40,41,42} The interaction with the tumor microenvironment is not a one way communication, and during tumor progression cancer cells also influence its own environment. This is evident, in the way tumor cells recruit bone marrow derived cells such as leukocytes, neutrophils and macrophages to the tumor stroma, that in turn interact with tumor cells e.g. by producing cytokines.^{43,44,45} Under these conditions, when both the intrinsic factors of the tumor cells and the pro metastatic microenvironment act together, tumor cells can turn motile and invasive.^{38,46}

As tumor cells turn invasive, they have the capacity to migrate towards blood and lymphatic vessels and intravasate into the circulation.⁴⁷ Tumor cells are known to produce pro angiogenic factors such as VEGF-A and VEGF-C, which promote both angiogenesis and lymphangiogenesis respectively.^{48,49,50} In the tumor micro environment blood and lymphatic vessels will in turn produce factors stimulating tumor cells, e.g. lymphatic vessels are known to produce chemokines that attract migratory tumor cells⁵¹. The blood vessels that are formed in the tumor microenvironment are known to be leaky and often lack normal coverage by pericytes and vascular smooth muscle cells, which makes them permeable, and tumor cells can disseminate to the circulation.^{52,53} Lymph vessels are on the other hand designed for trafficking of immune cells, and can also act as a route tumor cells into the circulation.^{54,55,56} Once in the circulation, breast cancer cells have the capacity to find and to form metastasis in distant organs such as lung, bone and liver.^{57,58}

1.3 Epithelial Ovarian Cancer Progression

Although a new classification of ovarian cancer, based on genetic profiles, has been developed dividing ovarian cancer into two broad groups of type I and type II, ovarian cancers are still divided into different subtypes including serious, endometrioid, clear cell, mucinous, and undifferentiated tumors based on morphological features. Serious carcinomas




Figure 1. Crosstalk between components in the tumor microenvironment and tumor cells drive tumor progression and invasion. Initially tumors grow in a confined epithelial compartment which is separated from underlying mesenchymal tissues by the basement membrane of the mammary duct. Throughout progression tumor cells secrete several factors such as EGF which establish (I) a paracrine circuit between tumor cells to sustain growth, and later as tumor cells enter the mesenchyme involve (II) recruitment of inflammatory cells with the capacity to either suppress or promote tumor progression, and (III) remodulation of the tumor stroma and interaction with stromal cells. Finally, tumor cells (IV) produce angiogenic factors that affect surrounding vasculature resulting in angiogenesis. In turn vessels produce chemokines serving as a gradient for tumor cells to migrate to. As tumor cells establish these connections, the route leading to blood circulation, becomes available.

are the most common types tumors of all EOC, and are divided into low (type I group) and high (type II group) grades tumors.^{6,59}

Different from many other types of cancers, ovarian cancer has generally not been linked to chemical carcinogens with mutagenic potential, and only a few mutations of e.g. p53, typical for serious high grade carcinomas, has been linked to onset of ovarian cancers.^{60,61,62} Epithelial cells of the ovary are known to proliferate at a low rate and generally stay quiescent. Only after ruptures of mature follicles to release oocytes, epithelial cells have to proliferate in order to repair the disrupted ovarian surface.⁶³ A large fraction of ovarian cancer develops at the epithelial subsurface of inclusion cysts, formed during ovulation.⁶⁴

Factors that increase the number of ovulatory cycles, such as early onset of menses and late menopause also increase the risk of acquiring ovarian cancer. Opposite, a reduced number of ovulatory cycles decrease the risk, and these factors include e.g. multiple pregnancies and prolonged lactation. It is difficult to detect early stages (I/II) of ovarian cancer since there are few specific symptoms of the disease and it is mostly during the later stages (III/IV), when the ovarian cancer already have started to spread that the diagnostics is being made.^{65,66,67,68,69} Once ovarian cancer cells are invasive, they can spread through both lymphatics, or via blood vessels to form metastasis in the parenchyma of the liver or lung. In addition ovarian cancer cells are also shed of from the ovary to form implants on the peritoneal surface, and this is made possible based on the anatomical structure, containing no barriers to prevent metastasis, in the peritoneal cavity.^{70,71,72,73}

1.4 Epithelial-Mesenchymal transition (EMT)

Largely our bodies consist of epithelial and mesenchymal cells that have defined differences coupled to their physiological functions in the context of where they grow. Epithelial cells cover all outer and the most inner surfaces of tubular and glandular structures in the human body. Their functions include building a protective barrier against the outside environment, facilitate transport of substances across the epithelium, and mediate secretion in the glandular structures.^{30,74,75,76} Mesenchymal cells, including fibroblasts and smooth muscle cells, are on the other hand located in stromal compartments of the body, and are separated from epithelial cells by the basement membrane. These type of cells need to be motile during tissue repair and remodeling, have supportive and contractile functions.^{77,78,79}

Yet, during development epithelial cells trans-differentiate into mesenchymal-like cells through Epithelial-Mesenchymal transition (EMT). Cycles of EMT and the reverse mesenchymal-epithelial transition (MET) is needed for proper formation of the embryo.^{5,80,81} However, EMT can also be reactivated in pathologies including cancer and fibrosis.^{4,82} During EMT, epithelial cells lose apical-basal polarity and their cell-cell adhesion to neighboring epithelial cells, and convert to mesenchymal-like cells that are characterized by front-back polarity, which allows cells to migrate in a directional manner through extracellular matrix.^{76,83} In cell culture, EMT is a visible process under magnification, and from growing in a cobblestone-like monolayer, epithelial cells undergoing EMT adopt a spindle-shaped mesenchymal morphology. At a molecular level, EMT induces reorganization of cytoskeletal proteins, loss of junction proteins and polarity complexes, and increased expression of MMPs with the capacity to modulate the extracellular matrix.^{4,84,85}

Although EMT has been observed in many *in vitro* models of cancer cells, the significance of EMT during cancer progression and its relevance in human cancer has been debated, mainly because of lacking evidence of EMT in clinical cancer samples.^{5,86} It has proved difficult to distinguish cancer cells with mesenchymal properties from other mesenchymal cells in the tumor stroma. However, observations from the invasive front reveal

cancer cells, expressing both epithelial and mesenchymal markers, which are spreading from the tumor mass into the adjacent stroma. Besides from breast cancer this has been observed in different types of cancers including colon, cervical, thyroid and ovarian cancer.^{87,88,89,90}

In addition, markers of EMT such as snail and slug have been shown to clinically correlate with disease relapse of both breast and ovarian carcinoma.^{91,92} EMT has also been linked to basal-like, and metaplastic breast carcinoma and higher malignancies grades, again indicating that EMT worsen the clinical outcome.⁹³ Induction of EMT is induced by many different growth factors both during development and in cancer, and these includes include Notch, epidermal growth factor (EGF), hepatic growth factor (HGF), Wnt factors, and Transformer growth factor β (TGF- β).^{94,95,96,97,98,99} Although several factors most likely cooperate to induce EMT in tumors, TGF- β stands out as a major EMT inducer in cancerous disease.¹⁰⁰

1.5 Transformer growth factor beta (TGF- β)

There are more than 30 factors belonging to the TGF- β family and they can be divided into two branches, one including bone morphogenetic proteins (BMPs), anti-muellerian hormone (AMH), and growth and differentiation factors (GDFs), and the other consisting of nodal, lefty, activin, and TGF- β .^{101,102,103} These factors are diversely expressed throughout development and in adulthood, to at a early stage e.g. promote differentiation of stem cells to regulate the body axis formation, and later maintain the homeostasis of the human body.^{102,104}

Transforming growth factor beta ligands, TGF- β 1, TGF- β 2 and TGF- β 3, are potent regulators of cell growth, differentiation and migration.¹⁰⁵ The different TGF- β isoforms signals through type I, II, III TGF- β receptors (TGF β RI, TGF β RII, and endoglin) to initiate downstream signaling pathways.^{106,107} When TGF- β 1 and TGF- β 3 ligands are expressed and activated, through proteolytic cleavage or structural modifications in the extracellular matrix and at the cell membrane, they bind to TGF β RII. The activated TGF- β 2 ligand is however dependent on the presence of the endoglin receptor to be able to bind TGF β RII with high affinity. When expressed, the TGF- β type 1 and type II receptors form homodimers in the endoplasmic reticulum (ER) and at the cell surface when ligands are not present. TGF- β ligands favor binding to TGF β RII homodimers forming a ligand-bound receptor complex that in turn has high affinity for binding to the TGF β RI receptors, resulting in an activated heteromeric signaling complex.^{106,108,109} Activin receptor-like kinase 5 (ALK5) is the predominantly expressed TGF β RI in most cell types, and is activated by TGF β binding to TGF β RII. Notably ALK5 signaling results in the activations of the transcriptional co-regulators SMAD2 and SMAD3, whereas ALK-1 or ALK-2 activate SMAD1, SMAD5 and SMAD8.^{110,111,112}

The functional T β RII-T β RI heteromeric signaling complex is generally linked to human cancer, and it regulates the induction of downstream SMAD-dependent and SMAD-independent pathways.¹¹³ Activation of this receptor complex, cause receptor-associated SMAD2 and SMAD3 to form homo and heterotrimeric complexes with the common mediator SMAD4. As these complexes forms they translocate to the nucleus where they regulate gene transcription and this is the canonical SMAD-dependent pathway of TGF β signaling.^{114,115} However, SMAD factors themselves only bind DNA with low affinity, and therefore need to cooperate with other transcription factors in order to gain high binding affinity to specific target genes.¹¹⁶ Various transcription factors, both activating and repressing gene expression are known to bind to the Smad complex, including forkhead, zinc-finger, bHLH, homeobox, and AP1 transcription factors.

In addition to the canonical SMAD signaling pathways, SMAD independent TGF β signaling networks are also activated by the TGF β RI-TGF β RII heteromeric complex, including Ras homolog gene family, member A (RHOA), Rat Sarcoma protein (RAS), Rho family, small GTP binding protein (RAC1), phosphatidylinositol 3-kinase (PI3K), Mitogen-activated protein kinase, kinase, kinase 1 (MEKK1), and TGF β activated kinase (TAK1)^{117,118} Activation of all these kinases induce various signaling cascades with capacities to promote different cellular processes.^{119,120}

1.5.1 Role of TGF- β in cancer

Under normal conditions, the basal release of TGF- β is sufficient to sustain tissue homeostasis.^{109,121} Conversely, in damage tissue during injury, TGF- β is produced at high levels by cells in the stromal compartment, in order to control regenerative cell proliferation and inflammation.^{122,123} It is important to know, that these conditions are activated in tumors as well, and that TGF- β is abundant in the tumor microenvironment. During early stages of tumor progression TGF- β act as a premalignant suppressor, while at later stages instead promote invasive and metastatic processes. In order to understand the dual nature of TGF- β signaling in cancer, one needs to consider the dynamic and contextual aspects of TGF- β induced pathways (Figure 2).^{124,125,126,127}

Mutation in the genes encoding TGF- β receptors have been detected in cancer, but inactivation of TGF β RII in specific tissues rarely leads to spontaneous formation of tumors.¹²⁸ In the mammary epithelium, deletion of TGF β RII causes lobular-alveolar cell proliferation in mice¹²⁹, but no pathological changes in other types of epithelia.¹³⁰ Rather, it is during oncogenic stress or tissue injury that the role of TGF- β in restricting epithelial growth becomes evident, and depletion of TGF β RII or SMAD4 accelerates the malignant progression or neoplastic lesions with oncogenic stimuli.^{131,132,133} This is observed in polya virus middle-T (PyMT) oncogene driven mammary tumors, where deletion of TGF β RII enhance carcinoma formation.¹²⁹ The cytostatic response to TGF- β is mediated through inhibition of the cell cycle in the G1 phase, through mobilization of cyclin-dependent kinase inhibitors and c-Myc suppression.¹³⁴ In epithelial cells FoxO transcription factors targets and activate p15INK4b and p21CIP1 promoters, leading to inhibition of cyclinD-cdk4/6 complexes through p15Ink4b and cyclinE/A-cdk2 complexes by p21Cip1.^{135,136}

As tumors progress the character of the TGF- β response changes, cytostatic effects are lost and instead TGF- β increase invasion and induce EMT.¹³⁷ As previously discussed, both intrinsic and extrinsic factors come into play when tumor cells turn invasive, and this is reflected in the TGF- β response. Many mediators of the non-canonical signaling cascade, downstream of the TGF- β receptor, are not exclusive to TGF- β signaling, but rather components utilized in different types of signaling systems. Thus, there are many signaling focal point that enable co-regulation of cellular responses between the TGF- β pathway and others induced by different growth factors in the tumor microenvironment. This is evident in the regulation of GSK-3 β , known to inactivate EMT promoting transcription factors, and targeted for inactivation downstream of both TGF- β and Wnt signaling.¹³⁸ Enhanced induction, through combined stimulation of TGF- β and other growth factors such as EGF and HGF has been observed. EGF and HGF both induce RAS signaling that activate RAF/ERK/MAPKinase pathways, leading to loss of cytostatic response to TGF- β and activation of EMT promoting transcription factors such as snail and twist through induction




Figure 2. SMAD dependent and independent pathways of TGF-β signaling, subjective to intracellular influence in cancer cells, determine the cellular response to TGF-β. Activation of the heteromeric receptor complex of TGF-βRI and RII upon TGF-β ligand binding results in the induction of SMAD-dependent signaling, involving formation of the SMAD complexes with other transcription factors (TFs), and SMAD-independent signaling mediated upstream by e.g. RHO-A, RAC, and RAS. Both signaling cascades are under the influence of many intrinsic factors that are altered in tumor cells, and oncogenic pressure and other growth factors have the potential to alter the cellular response of TGF-β from growth inhibition to EMT.

of high-motility group A protein 2 (HMGA2).^{139,140} Different members of the RAS protein family have been shown to induce EMT in various degrees.^{139,141,142} In addition to other signaling pathways, non-canonical TGF- β pathway is also under influence of oncogenic activity, whereas abnormal activity of oncogenes such as, Pten, p53, and C-MYC are known to promote EMT.^{143,144,145}

The dependence of SMAD complexes to interact with other transcription factors to bind and regulate target genes indicates that canonical TGF- β signaling is contextual.¹¹³ Indeed, studies of TGF- β induced EMT has revealed several transcription factors interacting with the SMAD proteins to promote EMT, including both transcriptional repressors and activators. The outcome of Smad-dependent TGF- β signaling is therefore reliant on the transcription factors available in the target cell. In conclusion, EMT requires both that SMAD-independent signaling is altered due to oncogenic pressure or combined exposure from cytokines, and the right mix of SMAD interacting transcription factors in the nucleus of the target cell.^{105,114,146}

1.6 Transcriptional regulation of EMT

Activation of TGF β signaling in breast cancer cells during pro-metastatic conditions can, as discussed, induce EMT. In order to carry out the specific changes in the tumor cells when they turn mesenchymal, it is required that mechanisms involved in transcriptional regulation are altered – that genes previously turned off are turned on, and the reverse. In order to regulate gene expression different systems has been developed in the cell, involving regulation of the transcriptional complex by transcription factors, epigenetic modifications, and post-transcriptional regulation.¹⁴⁷ In transcriptional machineries, all of these factors work together to promote or maintain cellular functions and phenotypes. By now different transcription factors promoting EMT has been identified, including both transcriptional repressors and activators. Many of these factors have been shown to interact directly to co-SMADs and are thus activated during TGF- β induced EMT.^{146,148}

During EMT transcriptional repressors will silence the expression of epithelial genes such as junction proteins. This is evident on the promoter of E-cadherin where Snail, Zeb and bHLH factors bind to repress the expression.^{91,149,150,151} In the E-Cadherin promoter this is mediated through binding of these factors to E-box sequences with a 5'-CACCTG-3' core motif.^{92,152,153} Binding of factors from the Snail family is generally thought to repress transcription through recruitment of chromatin remodeling complexes that silence the gene, although they can, in a context dependent manner, activate target genes as well.^{154,155} Snail1 is a major promoter of EMT in development and cancer, and overexpression alone is enough to induce EMT in cell culture.^{156,157} Snail overexpression has been shown to induce other repressors and is upregulated early during TGF- β induced EMT. In fact, a peak of Snail1 expression can be seen early after TGF- β stimulation in cultured epithelial cells.¹⁵⁸ Even if it is evident that factors of the Snail family regulate each other, these two aspects might suggest that Snail1 is essential to kick start EMT.

Transcriptional activators promoting EMT, on the other hand, will bind and increase the expression of mesenchymal genes and includes factors like B-catenin, AP-1, SP-1 and NF κ B transcription factors. B-catenin, activated by Wnt signaling, interacts with TCF4/LEF transcription factors to induce genes involved in EMT, such as Vimentin and Snail2.^{159,160} AP-1 promotes the expression of MMPs and is formed as heterodimers of jun-fos/fra proteins or as jun-jun homodimers and is known to promote invasiveness and metastatic capacity of cancer cells.¹⁶¹ As an activator of Snail1 and Twist expression NF κ B overexpression is sufficient to induce EMT in mammary epithelial cells.¹⁶²




Figure 3. A transcriptional switch during EMT involves both epithelial and mesenchymal transcriptional activators and repressors. One central part of the transcriptome is transcriptional regulation. To maintain the epithelial phenotype a set of different genes needs to be kept active in the cell involving polarization, cell-cell adhesion, and in ductal structures secretion. As epithelial cells form transcriptional repressors also needs to inactivate expression of genes promoting a non-epithelial cell fate, including mesenchymal genes. Reversed circumstances are found in mesenchymal cells where genes involved in the mesenchymal cell functions are activated and other genes repressed. During EMT, factors such as TGF- β switch the transcriptional machine of the cell, turning off epithelial transcription factors and turning on mesenchymal. This leads to phenotypical changes promoting a migratory behavior of otherwise stationary epithelial cells.

Although the transcriptional inducers of EMT have been well characterized and studied there is less known about transcription factors able to prevent EMT. Even so, it is logical to assume that transcriptional programs activated to promote and maintain the epithelial phenotype needs to be inactivated during EMT. In line with this, different transcription factors known to promote epithelial differentiation during development have been shown to prevent invasive behavior of tumor cells and also EMT. Due to the initial epithelial programs in the tumor cells e.g. KLF, BRCA, ELF family members have been known to inhibit EMT through activation or repression of target genes. Still, further evaluation is needed to determine the capacity of epithelial differentiation factors to prevent and even revert EMT.^{163,164,165,166,167,168}

1.6.1 CCAAT-enhancer binding protein beta

The CCAAT-enhancer binding protein (C/EBP) family transcription factors, consisting of 6 members (α - γ), are known to play crucial role in different cellular events including cellular proliferation, differentiation, metabolism and inflammation.¹⁶⁹ All factors within the C/EBP family contain the same leucine zipper domain at the C-terminus and they all share the capacity to bind to the CCAAT sequence of DNA. Although they all bind to the same sequence, the N-terminal part, which varies in size, of the C/EBP proteins enables different type of interactions and actions once bound to DNA.¹⁷⁰

The expression of C/EBP proteins varies throughout different tissues of the human body, and in mammary epithelial cells C/EBP β has been identified as differentiation factor towards luminal cell fate in the mammary epithelium and as regulator of branching morphogenesis.^{170,171,172} Through alternative splicing C/EBP β is produced in three isoforms, liver activation protein 1 and 2 (LAP1 and LAP2) both two transcriptional activators containing transactivation domains, and the shorter isoform liver inactivation protein (LIP). LIP is generally considered to act as a repressor of C/EBP β activity since it lacks the transactivation domain.¹⁷³

In breast cancer C/EBP β has been described as deregulated, and in some cases inducing proliferation of tumor cells^{174,175}, but the role of C/EBP β in cancer is not fully known. Different isoforms of C/EBP β , and the ratio of LIP and LAP has shown to be of importance.^{176,177} In line with this, inactivation of C/EBP β activity due to high LIP/LAP ratio is a mechanism of evasion from the cytostatic TGF- β response in breast cancer. In this study C/EBP β was shown to interact with Smad complexes to activate the expression of INK4b, encoding p15INK4b, a mechanism that was lost in metastatic breast cancer cells from pleural effusions.¹⁷⁸

1.6.2 Forkhead box P4

Forkhead box (Fox) proteins, a family that all contain a common forkhead box DNA binding domain are evolutionally conserved transcription factors. In total there are 19 subfamilies with around 50 genes, and they play various roles in different biological processes during development including differentiation, proliferation and apoptosis. Certain members of the fox family of proteins have been linked to epithelial plasticity of cancer cells and deregulated expression of these proteins has been related to increased malignancy and metastatic capacity.^{179,180}

Forkhead box P4 (FoxP4) found to be expressed in epithelial cells in different tissues, and have been described to play important roles in mediating differentiation.^{181,182,183}
¹⁸⁴ Foxp4 is expressed in the pulmonary epithelium where it promotes differentiation of secretory epithelial cells through inhibition of goblet cell differentiation.¹⁸² In neuroepithelial cells Foxp4 is known to transcriptionally repress N-cadherin in order to promote epithelial differentiation.¹⁸⁵ In mammary epithelial cells Foxp4 has been identified as a core transcription factor based on its enriched expression.¹⁸⁶ Although no studies have been performed specifically on the role of foxp4 in women's cancer it has been shown to be a target for oncogenic translocation in breast cancer.¹⁸⁷ In addition, it has been identified as a susceptibility locus for prostate cancer, and decreased levels of Foxp4 has been reported in kidney cancer.^{184,188}

1.7 Tight junctions

Epithelial cell layers form barriers that protect multicellular organisms from the external environment. Epithelial integrity is maintained by tight junctions, adherens junctions and desmosomes. Adherens junctions are formed by E-cadherin,¹⁸⁹ while transmembrane components of tight junctions include claudins, occluding,¹⁹⁰ and Ig-like proteins like the coxsackie- and adenovirus receptor (CAR), the junction adhesion molecules (JAMs) and CAR-like membrane protein (CLMP).^{190,191,192} Tight junction proteins such as occludins, claudins and the recently identified members of the large Ig superfamily, e.g. CAR, are all mediators of cell-cell adhesion. Tight junctions affect many cellular functions, including cytoskeletal dynamics, polarized vesicle trafficking and proliferation.¹⁹³ TJs control physiological flux of ions and solutes across the barrier and are regulated by different growth factors, cytokines and hormones.¹⁹⁴

Transmembrane components of TJs are located to the apical side of the cells facing the lumen, and binds to scaffolding proteins that have an intracellular location close to the membrane. In turn scaffolding proteins are bound to the actin filament, and together this forms a netlike structure that spans across the epithelium constituting the TJ barrier.^{195,196,197,198} Interestingly, many kinases, phosphatases and transcription factors have been described to localize at the TJs, indicating that not only do TJs regulate extracellular conditions and events, but also serve as a hub for intracellular signaling.^{199,200} Certain proteins, such as RAC, and protein kinase C (PKC) are recruited to the TJs to perform their functions,²⁰¹ others like transcription factors c-jun and c-fos are inactively stored at the TJs.²⁰² Upon deregulation or disruption of the TJ barrier factors belonging to the TJ hub are both activated and inactivate, possibly as a mechanism for the cell to quickly response to changed conditions.^{201,203}

1.5.1 Coxsackie- and adenovirus receptor (CAR)

The coxsackie- and adenovirus receptor (CAR) is a member of the large immunoglobulin-like receptor family and a component of epithelial tight junctions and was first identified as a receptor for coxsackie B and type C adenoviruses.^{204,205} Consequently, along with some other TJs, CAR serve as an entry point for viruses.²⁰⁶ TJs all share the ability to promote cell-cell adhesion, and many of the TJ components have been proven to be dispensable. CAR on the other hand is, together with a few other TJs, vital both during development and in adult mice. Depletion of CAR in development leads to malfunction of the heart, as CAR mediates contact between the discs of cardiomyocytes.^{191,207} Knock down of CAR in adult mice leads to dilation of the intestinal tract, acinar-to-ductal metaplasia of the exocrine pancreas, and cause lethality.²⁰⁸ CAR is downregulated early during TGF- β induced EMT, in a similar

fashion to E-cadherin by master EMT regulators, but the role of CAR in the EMT response is not clear.²⁰⁹

1.8 Treatment of women's cancer

One of the major hallmarks of cancer is the evasive behavior of tumor cells towards growth inhibitory and an apoptotic stimulus compared to normal cells, and was recognized early on in the field of oncology.³ In the mid 20th century it was discovered that alkylating agents originally derived from mustard gas, had the capacity to target fast dividing tumor cells, and once injected into patients with leukemia had a beneficial outcome increasing survival.²¹⁰ This kind of treatment, now including several agents essentially all targeting fast dividing cells, was termed chemotherapy, and is commonly used to treat patients with different types of cancerous diseases worldwide.²¹¹

In addition to chemotherapy, both radiation therapy, and removal of the tumors through surgery is the standard line of treatment for cancer.^{212,213} In ovarian cancer the bulk tumor is removed through cytoreductive surgery, which means that the entire visible tumor is removed and followed by adding heated chemotherapy drugs to the operated area. Breast tumors are removed surgically and followed up with chemotherapy afterwards. Based on the clinical features of tumors, a scheme and agents for chemotherapy is adopted individually for patients of breast and ovarian cancer.^{51,214} The commonly used drugs for breast cancer treatment include the anthracyclines doxorubicin and epirubicin, and the taxanes paclitaxel and docetaxel. In some cases these are used in combination with other drugs, like fluorouracil (5-FU), cyclophosphamide, and carboplatin. For ovarian cancer the standard approach is to combine platinum compounds such as cisplatin or carboplatin with taxane drugs like paclitaxel.^{215,216}

Cisplatin, the drug studied in this thesis, causes antitumoral effects through its ability to form DNA breaks and pronounced DNA damage, mainly in proliferative cells. Compared to carboplatin, there are more side effects in non-proliferative tissues associated with cisplatin, including oto-, nephro- and neurotoxicity.^{217,218} Besides from DNA damage, cisplatin induces apoptosis through non-nuclear targets, with mitochondria as a major one. This is due to the acute effects of cisplatin inducing reactive oxygen species (ROS) and binding to mitochondrial DNA (mtDNA).²¹⁹

In ovarian cancer, 70% of the patients will respond to platinum- and taxane-based chemotherapy after surgery, and in 50% of these patients no cancer can be detected after 5 months of treatment. In breast cancer approximately 20% of treated patients have a relapse over a 10-year period. Although the reduction of visible tumor is present in EOC, 75% of all patients will relapse within 3 years. For triple-negative breast cancer 20% of patients will relapse with signs of distant metastasis.^{6,220,221} In EOC and breast cancer recurrent cancer cells are difficult to treat since they have developed multiresistance towards chemotherapy.^{82,222} These facts indicate that further alternative approaches for cancer treatments are necessary in order to cure patients from the disease. As the field of cancer research is progressing, and other hallmarks of cancer besides cell proliferation and growth are being explored, many new therapies are under development e.g. immunotherapies and anti-angiogenic treatments.^{223,224,225}

2 AIMS OF THE STUDIES

- To characterize ovarian cancer cells resistant to cisplatin treatments in terms of EMT and cancer stem cell properties
- To Study the role of C/EBP β , as a transcriptional activator of junction proteins, in TGF- β induced EMT in breast cancer
- To investigate role of Foxp4, as a transcriptional repressor of mesenchymal genes, in TGF- β induced EMT in breast cancer
- To study the role of CAR in regulating the EMT response to TGF- β in breast cancer cells

3 RESULT AND DISCUSSION

3.1 Paper I

Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate

Chemotherapies have mostly been developed to target the cell proliferative behavior of tumor cells. However, EOC cells frequently get resistant to this kind of therapy and it is still not clear to which features of the EOC cells that resistance is coupled to, but data indicate that cisplatin resistant cells have more aggressive properties. The aims of this study was therefore to (i) investigate whether EOC cells induced to become resistant to cisplatin treatment develop EMT and cancer stem cell characteristics, and (ii) study alteration in mitochondrial status of these cells, since cisplatin has non-nuclear target effects.

First, human ovarian carcinoma, SKOV-3, cells were repeatedly treated with cisplatin for long term, to generate resistant (R) cells, or treated with EtBr to make cells deficient in mitochondrial DNA ($\rho 0$). To verify chemoresistant features, SKOV-3-R cells were treated with other platinum drugs including carboplatin, paclitaxel and 5-FU. Based on IC-50 values after 72 h of treatment, SKOV-3-R displayed many fold increased resistance to these drugs compared to parental SKOV-3 cells. These data confirm that the repeated cisplatin treatment generated multi resistance cells. In contrast SKOV-3- $\rho 0$ cells did not display increased resistance. Known genes for drug resistance, Bcl-2, and the efflux protein ABCG2, was not upregulated in SKOV-3-R cells.

Leading up to this collaborative effort, was the finding that SKOV-3-R cells displayed a more mesenchymal morphology, and my part was primarily to assist further investigation of this finding. Western Blot analysis showed decreased levels of E-cadherin and increased levels of Vimentin and Twist in SKOV-3-R cells compared to parental and $\rho 0$ cells. Immunofluorescent staining confirmed increased nuclear staining of Twist and Snail in SKOV-3-R cells, suggesting that these factors might contribute to induction of the EMT phenotype in resistant cells. Using an automated xCelligence® device, motility of SKOV-3-R cells was evaluated, and in comparison to parental cells, displayed greater motility.

Since a link between EMT and cancer stem cells (CSC) has previously been described,²²⁶ we were also interested to study expression of CSC markers and the capacity to form mammospheres in SKOV-3-R cells. In line with this, western blot analysis showed upregulation of known CSC markers CD44, CD117 and ALDH1 in SKOV-3-R cells compared to parental and $\rho 0$ cells, but not the stem cell markers Oct-4 and Nanog. Functional sphere forming assays, on low binding cell culture plastics, showed that SKOV-3-R had higher self-renewal capacity and compared to parental and $\rho 0$ cells did not lose viability over time. These data suggest that multi-resistant ovarian cancer cells after cisplatin treatment show CSC and EMT characteristics.

Based these findings, we were interested in investigated ways to target the stem cell and EMT features of the SKOV-3 cells in order to decrease cellular viability to drug treatment. Since tyrosin kinase receptor CD117 was one of the more upregulated markers in SKOV-3-R cells this was our first target. CD117 is blocked by imatinib mesylate (gleevec), thus SKOV-3-R cells were treated for 48 h with the gleevec singly and in combinations with cisplatin, whereafter they were allowed to recover in drug-free medium for another 72 h. In

these experiments imatinib mesylate, alone or in combination, had no effect on growth at any time point in SKOV-3-R. Similar negative results were obtained with ISCK03 (5 μ M), another inhibitor of CD117 that did not lower the IC₅₀ value for cisplatin in SKOV-3-R cells..

Taken together these results indicate that targeting CD117 did not restore toxicity to cisplatin in SKOV-3-R cells. Another feature of the SKOV-3-R cells discovered throughout the project was that the mitochondrial status was changed, and SKOV-3-R cells had increased mitochondrial mass compared to parental cells detected with potential-independent MitoTrackerGreen dye. This was supported by increased levels of the nucleus-encoded mitochondrial proteins voltage-dependent anion channel (VDAC) and cytochrome c. Since mitochondrial metabolism and cell death is known to be regulated by VDAC, partially through binding of hexokinase-II (HK-II), we further investigate HK-II levels in the SKOV-3-R cells. Indeed we found upregulated levels of HK-II in SKOV-3-R cells, and to a larger extent in SKOV-3- ρ_0 cells, which makes sense since they are devoid of ETC and respiration. 3-bromopyruvate (3-BP) is small molecule that have been shown to have antitumoral effects by targeting and inducing dissociation of HK-II, and we were curious to evaluate if SKOV-3-R was sensitive to this compound. Treatment with 3-BP in one dose for 48 h was enough to reduce proliferation in both parental and SKOV-3-R cells, however while parental cells could resume to normal growth under drug-free conditions during the next 72 h, SKOV-3-R cells was unable to. In addition, we found that 3-BP enhanced the antiproliferative effects of cisplatin.

Combination of drugs targeting different features of tumor cells and their environment, have shown promise to treat cancer, and this study belongs to this category of studies. In the described case, abnormal metabolic activity of HK-II in SKOV-3 cells, made them vulnerable to its inhibitor 3-BP. However in our attempts to target EMT and CSC features of the SKOV-3 cells, through CD117 inhibition, we had no effect. Further exploration and understanding of these processes in tumor cells might therefore be needed to be successful in such an endeavor.

3.2 Paper II

MiR-155-mediated loss of C/EBP β shifts the TGF- β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.

As previously discussed, multiple factors are involved in tumor progression and the induction of EMT, and needs to be taken into consideration in studies conducted on EMT. Although this is rational, TGF- β stands out as a major inducer of EMT and is frequently associated with EMT both *in vitro* and *in vivo* in cancer and development. Interestingly, TGF- β signaling has opposite roles in cancer, acting as a tumor suppressor at early a stage, and as a promoter of malignancy and EMT at a later stage. Data also suggest that the switch in TGF- β response actually revolves around factors involved in EMT, and the TGF- β switch might be a premise for EMT in cancer. Following this line of thought, and based on its previously described role in the cytostatic effects of TGF- β and being a differentiation factor in mammary epithelial cells, C/EBP β emerged as interesting transcription factor to study in EMT, and in paper II we aimed to test the hypothesis that loss of C/EBP β has a preventative role against TGF- β -induced EMT in breast cancer.

In order to study C/EBP β expression in breast cancer cells with a less differentiated phenotype potentially undergoing EMT, we performed immunofluorescent staining on human breast carcinoma samples and did subsequent confocal microscopy analysis. E-Cadherin, known to be lost in invasive cancer and common marker for EMT, was stained in combination with C/EBP β . In breast cancer samples of well-differentiated

ductal carcinoma *in situ* (DCIS), strong staining of E-cadherin was detected at cell–cell junctions, and pronounced nuclear C/EBP β staining was detected in the breast cancer cells. In a series of eight invasive ductal breast carcinomas, which had been classified according to their status of estrogen receptor, progesterone receptor and HER2, we next analyzed the expression of E-cadherin and C/EBP β . We found decreased expression of E-cadherin in areas of triple-negative tumors, and, in total, lower levels of E-cadherin in triple-negative tumors compared to tumors positive for estrogen receptor, progesterone receptor and HER2, or only HER2. Nuclear staining for C/EBP β was reduced in triple-negative tumors and linear regression analysis revealed a significant correlation ($P=0.0011$) between the expression of E-cadherin and C/EBP β in all tumors analyzed. Further analysis demonstrated significantly decreased expression of C/EBP β in E-cadherin-negative areas compared with E-cadherin-positive areas of the triple-negative breast tumors. In support of these finding we could in a mouse model of mammary cancer progression, with mice overexpressing the polyoma virus middle T antigen under the mouse mammary tumor virus promoter (MMTV-PyMT mice), find that C/EBP β expression was lost at an advanced stage of cancer at the age of 10 to 14 weeks. Co-staining for E-cadherin and C/EBP β in tumor sections from 10- and 14-week-old MMTV-PyMT mice showed loss of C/EBP β expression in E-cadherin-negative areas compared with E-cadherin-positive.

To explore the mechanisms of C/EBP β loss in breast cancer, we used an established model of TGF- β 1-induced EMT in namru mouse mammary gland (NMuMG) epithelial cells. Treatment with TGF- β 1, induce visible signs of EMT after 24 h in NMuMG cells, and at 48 h detectble changes in protein level of epithelial markers such as E-cadherin and gain mesenchymal markers e.g. Vimentin are present. Immunoflourent analysis of untreated NMuMG cells showed typical nuclear staining of C/EBP β , which was lost in cells treated with TGF- β 1 to undergo EMT. Further western blot analysis of C/EBP β showed that all three C/EBP β isoforms (LAP1, LAP2 and LIP) were decreased in TGF- β 1-treated NMuMG cells, and no obvious change in the ratio between LIP and LAP was detected. By comparison, TGF- β 1 treated mouse mammary Eph4 cells, lacking the capacity to undergo EMT, did not induce loss of C/EBP β , suggesting that loss of C/EBP β is an EMT specific event.

Interestingly C/EBP β was not downregulated at RNA level indicated by qPCR analysis, suggesting post transcriptional regulation of C/EBP β during EMT. Based on other studies, showing that Cebpb mRNA is a target of miR-155 in B-cells and macrophages^{227,228}, and that miR-155 is a known oncomiR in cancer²²⁹, we hypothesize that miR-155 might be a repressor of C/EBP β during TGF- β 1 induced EMT in breast cancer. To test this, NMuMG cells were transfected with a synthetic miR-155 inhibitor (50 nM), in combination with TGF- β 1 treatment to study whether the presence of the miR-155 inhibitor would rescue C/EBP β expression. We found that in the presence of the miR-155 inhibitor, the expression of C/EBP β was increased at baseline, and less repressed during EMT. On the contrary, transfection of NMuMG cells, with a synthetic miR-155 mimic (50 nM), resulted in decreased levels of C/EBP β at baseline, and further repression after TGF- β 1 treatment. Further analysis by qPCR showed that the expression levels of miR-155 were approximately 4.5-fold higher in NMuMG cells compared with Eph4 cells at baseline, and increased in NMuMG cells subjected to TGF- β 1. This experiment also shows that the expression level of C/EBP β (all isoforms) was considerably higher in Eph4 cells compared with NMuMG cells.

To study whether miR-155 mediated loss of C/EBP β could sensitize breast cancer cells to TGF- β 1 induced EMT, we set up a series of gain and loss of function experiments. Lentivirus mediated knock down of C/EBP β through overexpression of small hairpin RNA (shRNA), lead to reduced baseline expression of E-cadherin and CAR, and potentiated TGF- β 1 induced EMT, indicated by increased levels of vimentin and further suppression of E-cadherin and CAR expression. Conversely, transient overexpression of LAP2 in

NMuMG cells resulted in increased mRNA levels of *Cdh1* and *Cxadr* at baseline, and less repression of both genes in response to TGF- β 1 (2 ng/ml, 24 h).

Based on these data we wanted to examine the potential of C/EBP β to revert cells maintaining an EMT program back to the epithelial phenotype. In order to do so we treated NMuMG cells with TGF- β 1 for more than 14 days (long-term), which had been reported to induce robust EMT and evasion from the cytostatic effects of TGF- β . Next we transiently overexpressed LAP2 in these cells, which lead to increased protein levels of epithelial markers E-Cadherin and CAR. On the contrary, overexpression of LAP2 did not influence the expression of mesenchymal EMT markers, including master regulators such as Zeb1, Slug, Snail and Twist. Together, these data indicate that reactivation of C/EBP β only partially revert EMT cells back to their epithelial origin.

Next we wanted to study if C/EBP β levels in breast cancer cells would also affect the invasive behavior *in vitro* and the metastatic process *in vivo*. To do so, we used the 4T1 mammary tumor model, a TGF- β driven model of metastasis, and preformed loss of function experiments. Lentivirus mediated knock down of C/EBP β resulted in less expression of E-cadherin and increased expression of vimentin, and shCebpb expressing cells were more invasive in boyden chamber assays towards a TGF- β 1 gradient. We went on injecting 4T1 cells expressing shControl or shCebpb subcutaneously into the flank of syngeneic BALB/c mice, tumors were formed and surgically removed after 2 weeks. Measurements of tumor growth indicated that tumors with repressed cebpb expression grew slower compared to control, but two month after tumors were surgically removed had formed more metastasis in the lungs.

Our results indicated that C/EBP β levels could alter the outcome of TGF- β signaling promoting EMT, invasion and metastasis in breast cancer, and we were curious to study the underlying mechanisms further. Our results had shown that knock down C/EBP β was enough to reduce expression of E-cadherin and CAR, which lead us to hypothesize that C/EBP β can modulate the EMT response of TGF- β by acting as a transcriptional activator of junction proteins.

In order to address this hypothesis, computer-based software was used to scan for putative binding sites for C/EBP transcription factors in the genomic DNA promoter sequences of several genes encoding junction proteins, and sites were found in the promoters of following genes: *Cdh1*, *Cxadr*, *Cldn3*, and *Ocln*. Further, chromatin immunoprecipitation (ChIP) assays showed specific C/EBP β binding to the regions of putative binding sites in the promoters of the *Cdh1* and *Cxadr* genes in NMuMG cells. Since C/EBP β had the capacity to bind to these two promoters we performed promoter reporter assays to determine if C/EBP β also could activate them. These experiments showed that overexpression of C/EBP β activated the *Cdh1* promoter by twofold and the *Cxadr* promoter by 2.5-fold and that overexpression of LAP2 by itself was more potent than C/EBP β to activate the promoters. Knock down of C/EBP β resulted in less mRNA expression of *cdh1* and *cxadr*, while overexpression induced the expression. Treatment of TGF- β 1 to induce EMT, also caused C/EBP β to dissociate from the *cdh1* and *cxadr* promoters.

This study, in combination with the previous study on cytostatic response, suggests that C/EBP β , a transcription factor promoting epithelial cell differentiation, have the capacity to inhibit EMT and restore the TGF- β response towards growth inhibition. Even so, C/EBP β lacked the capacity to fully revert EMT, which might indicate that reversion of EMT, based on transcriptional regulation, demands altered action of other transcription factors as well.

3.3 Paper III

Foxp4 controls EMT in breast cancer cells by acting as a transcriptional repressor of Snail1

During the course of our studies we identified Foxp4, a novel member of the family of Forkhead box (Fox) P transcription factors, as a C/EBP β target gene in mammary epithelial cells (data not shown). Based on this, and recent published findings showing that Foxp4 is a repressor of N-cadherin in neuroepithelial cells, we initiated studies to elucidate whether Foxp4 could play a role in regulating EMT in breast cancer.

First we took a bioinformatical approach and performed meta-analysis of publically available gene data sets on breast cancer and normal mammary gland material, and we followed up with immunohistochemistry analysis on invasive breast cancer patient samples. The meta-analysis revealed that Foxp4 expression was decreased in invasive breast carcinoma compared to normal mammary gland, and a weak positive correlation between E-Cadherin expression and Foxp4 in invasive breast carcinoma samples. Immunohistochemical staining also supported these results showing that nuclear Foxp4 expression was decreased in invasive breast cancer and that cells expressing lower levels of E-Cadherin had significantly decreased levels of Foxp4.

These data suggested that foxp4 expression is lost in invasive cancer compared to normal mammary epithelium, an indication that maybe oncogenic conversion of epithelial cells is a causative effect of foxp4 loss. In particular, oncogenic variants of RAS have been linked to malignant progression and EMT of breast cancer cells. Thus, in order to study foxp4 expression during tumor progression driven by oncogenic HaRAS, we used a transgenic mouse model of inducible MMTV-HaRAS expression in Balb/c mice. Mice of this model develop mammary tumors that progress into invasive tumors with signs of EMT properties, and metastasize to the lungs. As tumors formed after 1-3 weeks of HaRAS activation, we observed downregulation of Foxp4 expression in the nuclei of cancer cells, and after 4 weeks of tumor progression we had close to non-detectable levels of Foxp4 in the tumor cells. To study whether HaRAS activation directly affects FoxP4 expression, we used adenovirus vectors to transiently overexpress HaRAS and KRAS in mouse mammary epithelial, EpH4, cells. Overexpression of either HaRAS or KRAS for 48 h resulted in decreased expression of FoxP4, both at mRNA and protein levels.

In line with the studies performed on C/EBP β , we wanted evaluate if foxp4 could impact TGF- β induced EMT, something that was also supported by our findings that foxp4 expression was decreased in invasive human breast cancer cells with signs of EMT. Again we used NMuMG cells, and induced expression of Foxp4 shRNA through lentivirus transduction. Knockdown of Foxp4 by itself was enough to induce an E-to-N-cadherin switch in NMuMG cells, and cause increased levels of vimentin. Further, treatment with TGF- β 1 for 48 h resulted in a more pronounced EMT phenotype in shFoxp4 compared to shControl expressing NMuMG cells. Knock down of Foxp4 also lead to increased invasive behavior of NMuMG cells in the boyden chamber assay, were cells migrated in matrigel towards a TGF- β 1 gradient.

As an additional experiment to further study the implications of reduced Foxp4 expression during EMT, we did knocked down of Foxp4 in mouse mammary EpRas tumor cells. Once injected into syngeneic BALB/c mice, these cells have the capacity to undergo EMT. Knockdown of Foxp4 in EpRas cells resulted in increased expression of N-cadherin and vimentin, reduced expression of E-cadherin and CAR, and increased invasive capacity *in*

vitro. Although knock down of Foxp4 did not affect tumor growth, immunofluorescence staining indicated that cells in tumors formed by shFoxp4 expressing cells expressed lower levels of E-cadherin and higher levels of N-cadherin compared to shControl tumors. Together, these results support the hypothesis that that loss of Foxp4 promotes EMT in both normal and transformed mammary epithelial cells.

Since Foxp4 is a known transcriptional repressor, but reverted both mesenchymal and epithelial genes during EMT, we hypothesized that Foxp4 transcriptionally repress one or several master regulators of EMT. To test this, we analyzed the expression of a set of master regulators including Snail1, Snail2, and Zeb1 in NMuMG cells after Foxp4 knock down. In NMuMG cells expressing shFoxp4, mRNA levels of Snail1, Snail2, and Zeb1 were increased compared to control shRNA. To evaluate if all these genes were directly repressed by Foxp4, or if the reduction was due to secondary effects, we instead transiently overexpressed Foxp4 and analyzed the mRNA expression at earlier time points. At a 24 h time point of Foxp4 overexpression no significant changes could be detected in mRNA levels for any of the genes, however at 48 h both *cdh2* and *snail* were significantly repressed but not *snai2* and *zeb1*.

As these results suggested that Snail1 might be a direct target of Foxp4, we did sequence analysis on the 1000 base pair promoter sequence located upstream of the first ATG of the mouse Snail gene, revealing three putative FoxP binding sites. Transfecting cells with luciferase reporter constructs containing full length or truncated versions (575, 300, 100 bp) of the *snail* promoter in combination with Foxp4 overexpression vector resulted in repression of the full length *snail* promoter. The repression by Foxp4 was only rescued when all three putative binding sites were truncated. In addition, ChIP assays verified binding of Foxp4 to the regions of these 3 putative binding sites in the *snail* promoter in NMuMG cells.

Knock down of Foxp4 in NMuMG cells resulted in increased mRNA levels of Snail1 at baseline compared to control cells and based on these results we next asked whether Snail1 also would be differently expressed during EMT in Foxp4 depleted cells. Following treatment with TGF- β 1 for 24h the induction of Snail in cells with impaired Foxp4 expression was robustly increased compared to control cells. At protein level the difference could be observed between control and Foxp4 knock down cells after 48 h TGF- β 1 treatment, however no detectable levels of Snail1 was found at baseline in both control and knock down. These data may indicate that increased RNA levels of Snail1 alone is not enough to increase protein levels of Snail1, and suggest that post transcriptional stabilization of Snail1 also needs to occur, something that is known to happen during TGF- β 1 induced EMT. Finally, immunohistochemical staining of human breast cancer samples showed increased staining of Snail1 in Foxp4 negative areas of tumors, perhaps implementing a clinical relevance of this mechanism since Snail1 is linked to a worse clinical outcome.

As a next step we were interested in investigating if reactivation of Foxp4 in breast cancer cells could revert cells back from EMT. Transient overexpression of Foxp4 in NMuMG cells resulted in slightly reduced levels of N-cadherin and vimentin, both at baseline and upon TGF- β 1 treatment for 24 h. In addition, downregulation of E-cadherin and CAR was partially rescued after TGF- β treatment in Foxp4 overexpressing cells compared to control. These data suggest that Foxp4 can inhibit induction of EMT. Next, we wanted to determine whether overexpression of Foxp4 could revert EMT in human breast cancer cells. For these studies, we used invasive human breast cancer MDA-MB-231 cells, which are known to display EMT properties. Stable, lentivirus-mediated overexpression of Foxp4 in MDA-MB-231 cells resulted in reduced expression of Snail1, N-cadherin and Vimentin, and increased expression of CAR. E-cadherin was not detected in these cells. These results indicated that overexpression of Foxp4 was sufficient to induce MET in human breast cancer

cells. In line with this, we found that Foxp4 overexpressing MDA-MB-231 cells were less invasive in the boyden chamber assay towards a TGF- β 1 gradient.

Based on our results, it will be of further interest to evaluate if Foxp4 overexpression in MDA-MB-231 and other invasive breast cancer cells will influence the course of tumor progression and metastatic process *in vivo*. Such experiments would be necessary in order to draw further conclusions about the role and significance of Foxp4 loss in breast cancer.

3.4 Paper IV

The Cocksackie- and Adenovirus Receptor Controls Akt Signaling and EMT in Breast Cancer Cells by Regulating Pten Localization and Stability at Tight Junctions

Study II and III both indicate that loss of transcription factors that normally promote epithelial differentiation is important for the induction of EMT. In this study we wanted to determine whether changes in tight junctions, which are closely linked to and essential for epithelial differentiation, play a role in EMT. In particular we were interested in CAR, since it is an essential TJ in adult mice. We set out to test the hypothesis that CAR could be involved in regulating the TGF- β response.

To test this hypothesis, we used EpRas and EpXT cells to perform gain and loss of function experiments. Knockdown of CAR in EpRas cells using siRNA did not affect expression of E-cadherin, Occludin and Vimentin after transfection, however with TGF- β 1 treatment further repression of both E-cadherin and occluding, and more induction of vimentin was induced in CAR knock down cells. In addition CAR knockdown lead to increased invasion towards a TGF- β 1 gradient in the boyden chamber assay. Overexpression CAR in EpXT cells for 48h on the other hand, resulted in increased expression of both E-cadherin and occludin, and decreased expression of Vimentin. EpXT cells overexpressing CAR were also less invasive compared to control cells. These data confirmed the hypothesis that CAR could regulate the EMT response in breast cancer cells.

As previously discussed tight junction act as a hub for intracellular signals, and this lead us on to study if CAR knock down could change known signaling pathways downstream of the TGF- β receptor. Western blot analysis on CAR knockdown versus control cells indicated that phosphorylation of Smad3 (pSmad3), p38 (p-p38) and ERK1/2 (p-ERK1/2) did not change neither at baseline nor after TGF- β 1 treatment for 1 h. On the other hand, phosphorylation of Akt (p-Akt) was more prominent in CAR knockdown cells than control cells, both at baseline and after TGF- β 1 treatment. Further, phosphorylation of Akt downstream target GSK-3 β was increased in CAR knockdown cells, and immunofluorescent staining of knock down cells indicated increased levels of nuclear Snail and Twist1. These results suggest that the branch of Akt signaling inducing EMT is activated in cells with impaired CAR expression.

Our next aim was to determine how CAR regulates Akt signaling in the cells. Interestingly, the phosphatase Pten, has been described to partially localize to tight junctions, and it is together with PI3K the major regulator of akt signaling. Pten localization to the TJs is mediated by interactions with the pdz-binding motif in the scaffolding proteins of MAGI protein family. One of the MAGI proteins, namely MAGI1, is also describe to interact with CAR, an interaction that is important for the recruitment and stabilization of MAGI1 to the TJs.^{230,231} Based on these notions we aimed to investigate if CAR could stabilize Pten at TJs, something that would suppress Akt signaling. Immunofluorescence analysis on mammary EpH4 cells, with the capacity to polarize, revealed that both Pten and CAR co-localized at the TJs together with Magi1. Supporting physical interactions between these three proteins, co-immunoprecipitation (Co-IP) experiments, using a MAGI1 antibody, precipitated both CAR

and Pten in EpH4 cells. Since CAR is lost gradually at TJs during TGF- β 1 induced EMT we were interested to study if a similar pattern would be seen with Pten and Magi1. Indeed when we induced EMT for 48h in EpRas cells we found that all three proteins were mainly lost at TJs and that only a dot-like staining remained. Neither could Pten be detected at the TJs in EpXT cells which are stably in EMT. Further siRNA mediated knock down of CAR resulted in increased phosphorylation of Pten, which is known to cause destabilization of the protein, and lower total protein levels of Pten. Conversely overexpression of CAR lead to less phosphorylation of Pten and increased total protein levels. These data indicate a role of CAR in stabilization of Pten at the TJs. Based on this, we finally treated CAR knock down cells with a PITenin, a PIP3 antagonist, to verify if Akt activation in CAR knock down cells is bound to the activity of PIP3 conversion by Pten. Inhibition of PIP3 in CAR knock down cells partially reversed the Akt activation in siCAR expressing EpRas cells.

This study indicates that cell differentiation goes beyond transcriptional regulation and that the other parts of the epithelial phenotype, in this case CAR expression, play a part in maintaining the epithelial phenotype during EMT. As previously discussed, there are hubs where the TGF- β pathway is connected with other signaling pathways, but the multi molecular perspective on signaling is still far from understood. The data presented in this study suggest that TJs might be one of these hubs, acting to suppress TGF- β signaling.

4 CONCLUSION

As we are rapidly increasing our knowledge of how tumors grow, turn invasive, and eventually metastasize to distant organs, we understand new levels of complexity from a molecular to multicellular level, and we are exploring many new ways to treat cancer patients, beyond the initial way to target uncontrolled cell growth. Our first study implies that this exploration might be fruitful, as inhibition of HKII, involved in metabolism, lead to re-sensitization of cisplatin treatment and less proliferation of SKOV-3-R cells. In addition to this successful attempt, we also study the changeable features of SKOV-3-R cells, and found them to display EMT and CSC characteristics. Something we observed, but were unable to utilize as treatments.

Although this study aim to find alternative ways of treating ovarian cancer, it is obvious from our study, that we are repeatedly going back to evaluate the (same old) cancer hallmark of uncontrolled cell growth and proliferation. Perhaps, as we are evaluating new therapeutics based on profoundly different molecular and cell-functional backgrounds, we also need to reinvent the design of our studies on drugs, and have courage to expand the variety of readouts not only concerning tumor cell growth. Successful treatment targeting transition may not at all concern cell growth, but still prove valuable for clinical outcome in patients. The limitations in design of this study might also indicate that we currently know too little about cell transition in general and in particular lack ideas of how to apply it to cancer therapies.

In the following studies of this thesis we made an attempt to penetrate the topics of cell conversion and EMT, to elucidate molecular mechanisms behind TGF- β driven breast cancer progression and invasion. Our reasoning behind all these three studies were that transition of tumor cells, from epithelial to mesenchymal-like, is made possible when factors maintaining the initial epithelial phenotype are lost. In study II and III we investigate the role of the two transcription factors C/EBP β and Foxp4, and in study IV the TJ and virus receptor CAR. All our studies pointed towards a role of these factors in determining breast cancer cells response to TGF- β .

In the C/EBP β study we found that loss of C/EBP β during EMT through miR-155 resulted in reduced expression of E-Cadherin and CAR. Interestingly, it is also known that Smad and LAP2 together induce G1 arrest through transcriptional activation of p15INK4b upon TGF- β 1 treatment, suggesting, together with our results, that the processes of cell growth and transition are linked together. In study III, Foxp4 was shown to, as a transcriptional repressor of Snail1, have the capacity to inhibit TGF- β induced EMT. In addition, this study indicates that oncogenic RAS signaling might trigger loss of Foxp4 in breast tumors, again showing a connection between cell growth and EMT. Regarding transcriptional regulation, these two studies together with many others on transcriptional EMT regulators, reveal that transcription programs involving repressors and activators are needed to maintain phenotypes and that alterations due to stimuli such as TGF- β can potentiate changes in cells morphology and functionality, causing EMT.

At a larger scale these studies hint towards the fact that molecules are versatile and shared between signaling pathways, used in different cellular processes, and linked together. In study IV we also find that CAR, previously thought of as a downstream target of TGF- β 1 induced EMT and functionally promoting cell adhesion, to have an extended role in cell signaling. In fact, CAR serves to maintain Pten functionality at TJs, thus regulating Akt signaling which is highly coupled to EMT, but also cell growth, and other cellular processes. In the three last studies we did not characterize breast cancer cells, but aimed to study EMT,

in a hypothesis driven manner. Interestingly this has led us to a point where we, to some degree, understand the basis of cellular transition, not as a separate ontology or category of cellular processes, but in a bigger context being integrated with many.

Based on this understanding, it might be possible that the transitory capacity of tumors can be used to e.g. reactivate growth inhibitory or apoptotic responses to currently used drugs, as a potential therapy for cancer. We might also attempt to use the changeable behavior to our advantage, by influencing the cellular fate of tumor cells. Potentially, this could be achieved through reactivation of factors similar to those being presented study II-IV, pushing cancer cells towards an epithelial cell fate, and preventing EMT. On the other hand, we know that many factors, both intracellular and extracellular, are involved in the induction of EMT, and that transition, in opposite to cell death, is not a terminal stage. Thus, it might prove difficult to first of all prevent EMT in cancer, and secondly to maintain suppression over a suspended period of time.

Potential differentiation therapies might therefore profoundly differ from traditional chemotherapy, where treatments cannot rapidly break processes e.g. to induce cell death, but instead needs to work together with existing genetic programs in the cancer cells to achieve beneficial outcomes such as less invasion and EMT. Although EMT of tumor cells towards an invasive stage is well integrated with most (by today) defined hallmarks of cancer, it seems nevertheless plausible that great therapeutic benefits from work on cellular transition and differentiation, will occur only if we go beyond these hallmarks and even the cancerous disease itself. Perhaps, work in accordance with genetic programs in a therapeutic purpose will prove to be lifelong treatments.

1 ACKNOWLEDGEMENTS

In order to discover new knowledge, gain understanding, and finally be able to use it to its full potential, it can never be enough to develop a great intellect. What is of equal importance is to develop your being - your creativity, joy and love. This hypothesis has constantly been confirmed to me during my years at Karolinska, I have meet many people that posses both in excess, and I'm ever grateful that so many of you have help me develop, not only my intellect, but most important my being.

On some roads in life guidance is fundamental, and in science I have been fortunate. In times when I have struggled to keep up, there has been unlimited support, advices, and motivation given to me. When I have been going too fast, someone has been there with the patience and comprehension to slow me down. Thank you **Jonas** for teaching me how to get ahead on this road, and although we are pretty slow runners in reality, it has been quite amazing how far and fast into the unknown world of cellular biology we manage to run together.

Enthusiastically, everyone in the Fuxe group has joined and contributed to the fun! **Tove**, it has been an inspiration to work together with you, and going back to the importance of possessing a great being... You are shining bright! To see skillfully and fast working hands in a lab is a lesson by itself, and besides from that I feel great gratitude to have known and worked with you **Meifong**. There are two people I would like to thank extra, that boosted me the last couple of miles, and that is **Laura**, an overflowing source of determination and energy, and **Oskar**, who steadily finds the right way. **Vedrana**, with great intelligence, you have a tremendous capacity to make things happen around you, and it was great to learn from that. **Azadeh**, you have all the qualities needed for the road ahead, so make sure to enjoy the road! Thank you, **Sandra** for the exciting time in the lab, and for selflessly chairing your brilliance. Early on, as I was throwing myself, head-first, into science there was one, always sensible and down to earth, voice next to me in the office, and for that I'm thankful **Maria**. **Jill**, you were always very cheerful and helpful as I was starting in the lab, and remain a good friend, so thank you for that!

We have had extended numbers of collaborations during my time in the lab. Standing out as an amazing and intelligent scientist, who has an impressive and well functioning lab, is **Derek**, and I feel very proud that you let me be a part of your group for some time in Florida. Of course you, **Magda**, are an essential contribution to Derek's success, and I admire your skills and talents a great deal! To both of you – thanks a lot! Further, I would like to thank **Mimmi** and **My**, for a really successful and fun collaboration. I would also like to express many thanks to **Aristi** for our joint effort to study the effects of selenium on EMT cells. As a part of the division of vascular biology, everyday is, to some extent, a collaboration where ideas, equipment and office space are shared between several groups, and I would like to thank especially **Erika**, **Johanna**, **Josefin**, **Linda**, **Lars J**, **Kristian**, **Daniel**, **Johan**, **Christer**, **Guillem**, and **Ulf** for making that happen. In general there are many of you working here at **Vascular Biology**, now or in the past, including **Barbra**, **Jennifer**, **Maarja**, **Maya**, **Lwaki**, **Pernilla**, **Colin**, **Radosa**, **Elizabeth R**, and **Sara C**, that deserves all the credit for being great colleagues and friends, that I shared a lot of fun with. Special thanks to our neighbors, **The Division of Structural Biology**, that are hosting/hosted some great scientists and friends including **Eddie**, **Bernie**, **Jason**, **Rajesh**, **Magnus**, **Robert**, and **Ömer**,

and **The Matrix Division**, with another bunch of great people that I'm happy to know including/included **Mark, Asi, Olle, Jaakko, Massa, Sergey** and **Juha**.

MBB's football team deserves its own paragraph. It's been the height of my career as football player to once per year, after hard training mixed with beers, represent our department at the KI cup. Sadly I only got to hear about the former glory and never won, but still a huge experience. Belonging to that team: **Bernie, Jennifer, Radiosa, David, Colin, Eddie, Massa, Asi, Jaakko, Bruno,** and **Juha**. Thanks for all the fun!

Jag vet att det jag har gjort kan tyckas väldigt långt borta, men jag vill väldigt gärna att ni ska förstå att jag inte hade kunnat genomföra detta om det inte varit för allt det stöd jag har haft, och all den kärlek ni har givit mig. Helheten inom mig, är beroende av de människor som varit mig nära, och det krävs en helhet för att avsluta jobbet.

Centralt i det hela är självklart min pappa, **Leif**, och min mamma, **Stina**, som genom sitt arbete möjliggjort att jag har kunnat följa mina drömmar. Under hela mitt liv har jag tagit del av hur vackert ni skapat världen omkring er, genom att bygga hus, upprätta trädgårdar, sköta djur och mark, och samtidigt alltid tagit hand om och varit där för oss i familjen. I allt detta – i det ni skapat, har jag min grund, och det är jag otroligt lycklig och tacksam över.

Jag vill tacka min bror, **Jonas**, för din positiva inställning och entusiasm till de saker du brinner för. Det är alltid lika kul att ta del av det! På sätt och vis var jag nog din första elev också, då jag som liten fick lära mig en massa om fiske etc. från dig, och nu känns det bra att veta att fler än mig har den förmånen.

Till min älskade syster, **Sanna**, vill först och främst tacka för ditt orubbliga stöd och för att du alltid tagit hand om din lillebror. Jag är otroligt stolt över dig, och jag har alltid för avsikt att försöka vara lika stark och fin mänskliga som du.

Sedan har vi **Alice, Hugo, Astrid** och **Oskar** som det alltid är lika roligt att träffa, som fyller mig med glädje, och gör mig till en lyckosam morbror/farbror. Jag är övertygad om att ni alla blir en del av samma positiva energi som har fört mig genom livet, och jag är förväntansfull över att se vart den bär er! Lyckligtvis har vi också **Nina**, och **David**, och all släkt i övrigt som alla har en plats i mitt hjärta!

Jag inser också att jag har mängder av vänner i olika städer som format mig till det bättre, och några vill jag tacka extra: **Jocke, Jonas Ö, Robert, Viktor, Mattias E, Henrik, Andre, Markus, Ellinor, Karin, Anna M, Laura B, Mattias O, Mohammed, Christian, Mara, Anna McCarthy, Wouter, Eleonora, Anton,** och **Sanna G**.

2 REFERENCES

- 1 Niehrs, C. Regionally specific induction by the Spemann-Mangold organizer. *Nat Rev Genet* **5**, 425-434 (2004).
- 2 Tam, P. P. L. & Loebel, D. A. F. Gene function in mouse embryogenesis: get set for gastrulation. *Nat Rev Genet* **8**, 368-381 (2007).
- 3 Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell* **100**, 57-70 (2000).
- 4 Nieto, M. A. & Cano, A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. *Semin. Cancer Biol.* **22**, 361-368.
- 5 Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. *Cell* **139**, 871-890 (2009).
- 6 International Agency for Research on Cancer, a. W. h. o. WHO classification of tumours of female reproductive organs *Lyon: International Agency for Research on Cancer* (2014).
- 7 Schiller, J. T. & Davies, P. Delivering on the promise: HPV vaccines and cervical cancer. *Nat Rev Micro* **2**, 343-347 (2004).
- 8 Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. *Nat Rev Cancer* **3**, 502-516 (2003).
- 9 Grayson, M. Breast cancer. *Nature* **485**, S49-S49.
- 10 Brenton, J. D., Carey, L. A., Ahmed, A. A. & Caldas, C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? *J. Clin. Oncol.* **23**, 7350-7360 (2005).
- 11 Shipitsin, M. Molecular definition of breast tumor heterogeneity. *Cancer Cell* **11**, 259-273 (2007).
- 12 Naderi, A. A gene-expression signature to predict survival in breast cancer across independent data sets. *Oncogene* **26**, 1507-1516 (2007).
- 13 Neve, R. M. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515-527 (2006).
- 14 Sotiriou, C. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc. Natl Acad. Sci. USA* **100**, 10393-10398 (2003).
- 15 Jones, C. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. *Cancer Res.* **64**, 3037-3045 (2004).
- 16 Booth, B. W. & Smith, G. H. Estrogen receptor-[alpha] and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. *Breast Cancer Res.* **8**, R49 (2006).
- 17 Iwanaga, R. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-[beta] signaling pathways. *Breast. Cancer Res.* **14**, R100.
- 18 Abd El-Rehim, D. M. Expression of luminal and basal cytokeratins in human breast carcinoma. *J. Pathol.* **203**, 661-671 (2004).
- 19 Jumppanen, M. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. *Breast Cancer Res.* **9**, R16 (2007).
- 20 Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. *Nature Rev. Cancer* **4**, 448-456 (2004).
- 21 Dell'eva, R. Carcinogenesis (2006).
- 22 Cheng, L. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. *Oncogene* **29**, 5700-5711.

- 23 Cho, R. J. Transcriptional regulation and function during the human cell cycle. *Nature Genet.* **27**, 48-54 (2001).
- 24 O'Dwyer, P. J., Johnson, S. W. & Hamilton, T. C. *Cancer Principles and Practices of Oncology*, 418-432 (1997).
- 25 Stewart, C. F. & Ratain, M. J. *Cancer: Principles and Practice in Oncology*, 452-467 (1997).
- 26 Tward, A. D. Distinct pathways of genomic progression to benign and malignant tumors of the liver. *Proc. Natl Acad. Sci. USA* **104**, 14771-14776 (2007).
- 27 Scott, K. L. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. *Cancer Cell* **20**, 92-103.
- 28 Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* **136**, 823-837 (2009).
- 29 Hahn, W. C. & Weinberg, R. A. Modelling the molecular circuitry of cancer. *Nature Rev. Cancer* **2**, 331-341 (2002).
- 30 Joshi, K., Smith, J. A., Perusinghe, N. & Monaghan, P. Cell proliferation in the human mammary epithelium. Differential contribution by epithelial and myoepithelial cells. *Am. J. Pathol.* **124**, 199-206 (1986).
- 31 Maragoudakis, M. E. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. *Kidney Int.* **43**, 147-150 (1993).
- 32 Ancsin, J. B. & Kisilevsky, R. Laminin interactions important for basement membrane assembly are promoted by zinc and implicate laminin zinc finger-like sequences. *J. Biol. Chem.* **271**, 6845-6851 (1996).
- 33 Orkin, R. W. A murine tumor producing a matrix of basement membrane. *J. Exp. Med.* **145**, 204-220 (1977).
- 34 Schittny, J. C. & Yurchenco, P. D. Basement membranes: molecular organization and function in development and disease. *Curr. Opin. Cell Biol.* **1**, 983-988 (1989).
- 35 Timpl, R. Laminin: a glycoprotein from basement membranes. *J. Biol. Chem.* **254**, 9933-9937 (1979).
- 36 van der Flier, A. & Sonnenberg, A. Function and interactions of integrins. *Cell Tissue Res.* **305**, 285-298 (2001).
- 37 Rabinovitz, I. & Mercurio, A. M. The integrin [alpha]6[beta]4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures. *J. Cell Biol.* **139**, 1873-1884 (1997).
- 38 Bissell, M. J., Kenny, P. A. & Radisky, D. C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. *Cold Spring Harb. Symp. Quant. Biol.* **70**, 1-14 (2005).
- 39 Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. *EMBO J.* **16**, 2783-2793 (1997).
- 40 Cunha, G. R. & Matrisian, L. M. It's not my fault, blame it on my microenvironment. *Differentiation* **70**, 469-472 (2002).
- 41 Allinen, M. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell* **6**, 17-32 (2004).
- 42 Bissell, M. J. & Labarge, M. A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? *Cancer Cell* **7**, 17-23 (2005).
- 43 Coussens, L. M. & Werb, Z. Inflammation and cancer. *Nature* **420**, 860-867 (2002).
- 44 Karin, M. Inflammation and cancer: the long reach of Ras. *Nature Med.* **11**, 20-21 (2005).
- 45 Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* **7**, 211-217 (2005).

- 46 Lopez-Novoa, J. M. & Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. *EMBO Mol Med* **1**, 303-314, doi:10.1002/emmm.200900043 (2009).
- 47 Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumor angiogenesis and metastasis- correlation in invasive breast carcinoma. *N. Engl. J. Med.* **324**, 1-8 (1991).
- 48 Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nature Med.* **1**, 27-31 (1995).
- 49 Kadambi, A. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. *Cancer Res.* **61**, 2404-2408 (2001).
- 50 Skobe, M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nature Med.* **7**, 192-198 (2001).
- 51 Balkwill, F. Cancer and the chemokine network. *Nature Rev. Cancer* **4**, 540-550 (2004).
- 52 Bates, D. O. & Harper, S. J. Regulation of vascular permeability by vascular endothelial growth factors. *Vascul. Pharmacol.* **39**, 225-237 (2002).
- 53 Less, J. R., Skalak, T. C., Sevick, E. M. & Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. *Cancer Res.* **51**, 265-273 (1991).
- 54 Pepper, M. S. Lymphangiogenesis and tumor metastasis: more questions than answers. *Lymphology* **33**, 144-147 (2000).
- 55 Karpanen, T. & Alitalo, K. Lymphatic vessels as targets of tumor therapy. *J. Exp. Med.* **194**, F37-F42 (2001).
- 56 Jia, Y. T. *et al.* Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. *World J Gastroenterol* **10**, 3261-3263 (2004).
- 57 Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nature Rev. Cancer* **3**, 453-458 (2003).
- 58 Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M. & Steeg, P. S. Breast cancer metastasis to the central nervous system. *Am. J. Pathol.* **167**, 913-920 (2005).
- 59 Vang, R., Shih Ie, M. & Kurman, R. J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. *Adv Anat Pathol* **16**, 267-282, doi:10.1097/PAP.0b013e3181b4fffa00125480-200909000-00001 [pii] (2009).
- 60 Hall, J. Critical evaluation of p53 as a prognostic marker in ovarian cancer. *Exp. Rev. Mol. Med.* **12**, 1-20 (2004).
- 61 Havrilesky, L. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. *J. Clin. Oncol.* **21**, 3814-3825 (2003).
- 62 Berchuck, A. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. *Gynecol. Oncol.* **52**, 232-236 (1994).
- 63 Das, P. M. & Bast, R. C Jr. Early detection of ovarian cancer. *Biomarkers Med.* **2**, 291-303 (2008).
- 64 Kurman, R. J. & Shih Ie, M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. *Hum Pathol* **42**, 918-931, doi:S0046-8177(11)00137-7 [pii]10.1016/j.humpath.2011.03.003.
- 65 Goff, B. A. Ovarian carcinoma diagnosis. *Cancer* **89**, 2068 (2000).
- 66 Iwabuchi, H. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. *Cancer Res.* **55**, 6172-6180 (1995).
- 67 Schwartz, D. R. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. *Cancer Res.* **63**, 4722-4729 (2002).
- 68 Shridhar, V. Genetic analysis of early- versus late-stage ovarian tumors. *Cancer Res.* **61**, 5895-5904 (2001).

- 69 Marquez, R. T. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. *Clin. Cancer Res.* **11**, 6116 (2005).
- 70 Schober, M. & Perrimon, N. Unconventional ways to travel. *Nature Cell Biol.* **4**, E211-E212 (2002).
- 71 Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. *Nature Rev. Cancer* **2**, 563-572 (2002).
- 72 Nagy, J. A. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. *Cancer Res.* **55**, 360-368 (1995).
- 73 Feeley, K. M. & Wells, M. Precursor lesions of ovarian epithelial malignancy. *Histopathology* **38**, 87 (2001).
- 74 Tepass, U., Tanentzapf, G., Ward, R. & Fehon, R. Epithelial cell polarity and cell junctions in *Drosophila*. *Annu. Rev. Genet.* **35**, 747-784 (2001).
- 75 Stingl, J., Eaves, C. J., Zandieh, I. & Emerman, J. T. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. *Breast Cancer Res. Treat.* **67**, 93-109 (2001).
- 76 Frisch, S. M. The epithelial cell default-phenotype hypothesis and its implications for cancer. *Bioessays* **19**, 705-709 (1997).
- 77 Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. *Nature Rev Immunol* **8**, 726-762 (2008).
- 78 Wu, Y., Chen, L., Scott, P. G. & Tredget, E. E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. *Stem Cells* **25**, 2648-2659 (2007).
- 79 Constantin, G. *et al.* Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. *Stem Cells* **27**, 2624-2635 (2009).
- 80 Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in health and disease. *Annu. Rev. Cell Dev. Biol.* **27**, 347-376.
- 81 Kerosuo, L. & Bronner-Fraser, M. What is bad in cancer is good in the embryo: importance of EMT in neural crest development. *Semin Cell Dev Biol* **23**, 320-332, doi:S1084-9521(12)00052-3 [pii]10.1016/j.semcd.2012.03.010.
- 82 Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial-Mesenchymal Transitions in Development and Disease. *Cell* **139**, 871-890, doi:<http://dx.doi.org/10.1016/j.cell.2009.11.007> (2009).
- 83 Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. *J Clin Invest* **119**, 1420-1428, doi:39104 [pii]10.1172/JCI39104 (2009).
- 84 Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelialâ€mesenchymal transition. *Nat Rev Mol Cell Biol* **15**, 178-196.
- 85 Craene, B. D. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer* **13**, 97-110.
- 86 Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. *Nature Rev. Cancer* **2**, 442-454 (2002).
- 87 Prall, F. Tumour budding in colorectal carcinoma. *Histopathology* **50**, 151-162, doi:HIS2551 [pii]10.1111/j.1365-2559.2006.02551.x (2007).
- 88 Wicki, A. *et al.* Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* **9**, 261-272, doi:S1535-6108(06)00086-9 [pii]10.1016/j.ccr.2006.03.010 (2006).
- 89 Sarrío, D. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res.* **68**, 989-997 (2008).
- 90 Wyckoff, J. B. *et al.* Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. *Cancer Res* **67**, 2649-2656, doi:67/6/2649 [pii]10.1158/0008-5472.CAN-06-1823 (2007).
- 91 Casas, E. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. *Cancer Res.* **71**, 245-254.

- 92 Hajra, K. M., Chen, D. Y. & Fearon, E. R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. *Cancer Res.* **62**, 1613-1618 (2002).
- 93 Sanchez-Tillo, E. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. *Cell. Mol. Life Sci.* **69**, 3429-3456.
- 94 Lim, J. & Thiery, J. P. Alternative path to EMT: regulation of apicobasal polarity in *Drosophila*. *Dev Cell* **21**, 983-984, doi:S1534-5807(11)00527-2 [pii]10.1016/j.devcel.2011.11.017.
- 95 Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. *Oncogene* **19**, 6550-6565 (2000).
- 96 Stein, U. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. *Nature Med.* **15**, 59-67 (2009).
- 97 Espinoza, I. & Miele, L. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. *Cancer Lett* **341**, 41-45, doi:S0304-3835(13)00602-2 [pii]10.1016/j.canlet.2013.08.027.
- 98 Wu, Z. Q. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic breast cancer 1, early onset (BRCA1) repression. *Proc. Natl Acad. Sci. USA* **109**, 16654-16659.
- 99 Horvay, K., Casagrande, F., Gany, A., Hime, G. R. & Abud, H. E. Wnt signaling regulates Snai1 expression and cellular localization in the mouse intestinal epithelial stem cell niche. *Stem Cells Dev.* **20**, 737-745.
- 100 Bhowmick, N. A. Transforming growth factor- β 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Mol. Biol. Cell* **12**, 27-36 (2001).
- 101 Lee-Hoeflich, S. T. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. *EMBO J.* **23**, 4792-4801 (2004).
- 102 Derynck, R. & Akhurst, R. J. Differentiation plasticity regulated by TGF- β family proteins in development and disease. *Nature Cell Biol.* **9**, 1000-1004 (2007).
- 103 Muller, P. Differential diffusivity of Nodal and Lefty underlies a reaction-diffusion patterning system. *Science* **336**, 721-724.
- 104 Mullen, A. C. Master transcription factors determine cell-type-specific responses to TGF- β signaling. *Cell* **147**, 565-576.
- 105 Massague, J. How cells read TGF- β signals. *Nature Rev. Mol. Cell Biol.* **1**, 169-178 (2000).
- 106 Wrana, J. L. TGF β signals through a heteromeric protein kinase receptor complex. *Cell* **71**, 1003-1014 (1992).
- 107 Yi, J. Y., Shin, I. & Arteaga, C. L. Type I transforming growth factor- β receptor binds to and activates phosphatidylinositol 3-kinase. *J. Biol. Chem.* **280**, 10870-10876 (2005).
- 108 Shi, Y. & Massague, J. Mechanisms of TGF- β signaling from cell membrane to the nucleus. *Cell* **113**, 685-700, doi:S009286740300432X [pii] (2003).
- 109 Lebrin, F., Deckers, M., Bertolino, P. & Ten Dijke, P. TGF- β receptor function in the endothelium. *Cardiovasc Res.* **65**, 599-608 (2005).
- 110 Tojo, M. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor- β . *Cancer Sci.* **96**, 791-800 (2005).
- 111 Muraoka-Cook, R. S. Activated type I TGF β receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. *Oncogene* (2005).
- 112 Desgrosellier, J. S., Mundell, N. A., McDonnell, M. A., Moses, H. L. & Barnett, J. V. Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. *Dev. Biol.* **280**, 201-210 (2005).
- 113 Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF- β family signalling. *Nature* **425**, 577-584 (2003).
- 114 Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. *Genes Dev.* **19**, 2783-2810 (2005).

- 115 Ross, S. Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. *EMBO J.* **25**, 4490-4502 (2006).
- 116 Vincent, T. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-[beta] mediated epithelial-mesenchymal transition. *Nature Cell Biol.* **11**, 943-950 (2009).
- 117 Holm, T. M. Noncanonical TGF[beta] signaling contributes to aortic aneurysm progression in Marfan syndrome mice. *Science* **332**, 358-361.
- 118 Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. *Cell Tissue Res.* **347**, 11-20.
- 119 Moustakas, A. & Heldin, C. H. Non-Smad TGF-[beta] signals. *J. Cell Sci.* **118**, 3573-3584 (2005).
- 120 Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F. & Weinberg, R. A. TGF-[beta]-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. *Nature Cell Biol.* **3**, 708-714 (2001).
- 121 Bombara, C. & Ignatz, R. A. TGF-[beta] inhibits proliferation of and promotes differentiation of human promonocytic leukemia cells. *J. Cell. Physiol.* **153**, 30-37 (1992).
- 122 Kulkarni, A. B. Transforming growth factor-[beta]1 null mutation in mice causes excessive inflammatory response and early death. *Proc. Natl Acad. Sci. USA* **90**, 770-774 (1993).
- 123 Reibman, J. Transforming growth factor [beta]1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. *Proc. Natl Acad. Sci. USA* **88**, 6805-6809 (1991).
- 124 Akhurst, R. J. & Derynck, R. TGF-[beta] signaling in cancer-a double-edged sword. *Trends Cell Biol.* **11**, S44-S51 (2001).
- 125 Derynck, R., Akhurst, R. J. & Balmain, A. TGF-[beta] signaling in tumor suppression and cancer progression. *Nature Genet.* **29**, 117-129 (2001).
- 126 Tang, B. TGF-[beta] switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. *J. Clin. Invest.* **112**, 1116-1124 (2003).
- 127 Bierie, B. & Moses, H. L. TGF-[beta] and cancer. *Cytokine Growth Factor Rev* **17**, 29-40 (2006).
- 128 Kim, S. J., Im, Y. H., Markowitz, S. D. & Bang, Y. J. Molecular mechanisms of inactivation of TGF-[beta] receptors during carcinogenesis. *Cytokine Growth Factor Rev.* **11**, 159-168 (2000).
- 129 Forrester, E. *et al.* Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. *Cancer Res* **65**, 2296-2302, doi:65/6/2296 [pii]10.1158/0008-5472.CAN-04-3272 (2005).
- 130 Lu, S. L. *et al.* Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. *Genes Dev* **20**, 1331-1342, doi:20/10/1331 [pii]10.1101/gad.1413306 (2006).
- 131 Ashcroft, G. S. *et al.* Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. *Nat Cell Biol* **1**, 260-266, doi:10.1038/12971 (1999).
- 132 Biswas, S. *et al.* Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. *Cancer Res* **64**, 4687-4692, doi:10.1158/0008-5472.CAN-03-325564/14/4687 [pii] (2004).
- 133 Munoz, N. M. *et al.* Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. *Cancer Res* **66**, 9837-9844, doi:66/20/9837 [pii]10.1158/0008-5472.CAN-06-0890 (2006).
- 134 Matsuura, I. Cyclin-dependent kinases regulate the antiproliferative function of Smads. *Nature* **430**, 226-231 (2004).
- 135 Naka, K. TGF-[beta]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. *Nature* **463**, 676-680.
- 136 Rich, J. N., Zhang, M., Datto, M. B., Bigner, D. D. & Wang, X. F. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. *J Biol Chem* **274**, 35053-35058 (1999).

- 137 Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF- β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. *J. Cell Biol.* **127**, 2021-2036 (1994).
- 138 Labbe, E. Transcriptional cooperation between the transforming growth factor- β and Wnt pathways in mammary and intestinal tumorigenesis. *Cancer Res.* **67**, 75-84 (2007).
- 139 Watanabe, S. *et al.* HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. *Am J Pathol* **174**, 854-868, doi:S0002-9440(10)60945-5 [pii]10.2353/ajpath.2009.080523 (2009).
- 140 Thuault, S. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. *J. Biol. Chem.* **283**, 33437-33446 (2008).
- 141 Daly, A. C., Vizan, P. & Hill, C. S. Smad3 protein levels are modulated by Ras activity and during the cell cycle to dictate transforming growth factor- β responses. *J Biol Chem* **285**, 6489-6497, doi:M109.043877 [pii]10.1074/jbc.M109.043877.
- 142 Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. *Nat Rev Mol Cell Biol* **9**, 517-531, doi:nrm2438 [pii]10.1038/nrm2438 (2008).
- 143 Chang, C. J. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. *Nature Cell Biol.* **13**, 317-323.
- 144 Wu, X. Evidence for regulation of the PTEN tumor suppressor by a membrane- localized multi-PDZ domain containing scaffold protein MAGI-2. *Proc. Natl Acad. Sci. USA* **97**, 4233-4238 (2000).
- 145 Seoane, J. TGF β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. *Nature Cell Biol.* **3**, 400-408 (2001).
- 146 Fuxe, J., Vincent, T. & Garcia de Herreros, A. Transcriptional crosstalk between TGF- β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. *Cell Cycle* **9**, 2363-2374, doi:12050 [pii].
- 147 Martin, J. A. & Wang, Z. Next-generation transcriptome assembly. *Nat Rev Genet* **12**, 671-682.
- 148 Massague, J. TGF β in cancer. *Cell* **134**, 215-230 (2008).
- 149 Spaderna, S. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. *Cancer Res.* **68**, 537-544 (2008).
- 150 Olmeda, D. Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. *Oncogene* **27**, 4690-4701 (2008).
- 151 Eckert, M. A. Twist1-induced invadopodia formation promotes tumor metastasis. *Cancer Cell* **19**, 372-386.
- 152 Sanchez-Tillo, E. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. *Oncogene* **29**, 3490-3500.
- 153 Espada, J. Regulation of SNAIL1 and E-cadherin function by DNMT1 in a DNA methylation-independent context. *Nucleic Acids Res.* **39**, 9194-9205.
- 154 Takkunen, M. Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. *J. Histochem. Cytochem.* **54**, 1263-1275 (2006).
- 155 Reinke, L. M., Xu, Y. & Cheng, C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. *J. Biol. Chem.* **287**, 36435-36442.
- 156 Cano, A. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nature Cell Biol.* **2**, 76-83 (2000).
- 157 De Craene, B. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. *Cancer Res.* **65**, 6237-6244 (2005).
- 158 Medici, D., Hay, E. D. & Olsen, B. R. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor- β 3. *Mol Biol Cell* **19**, 4875-4887, doi:E08-05-0506 [pii]10.1091/mbc.E08-05-0506 (2008).

- 159 Gradl, D., Kuhl, M. & Wedlich, D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. *Mol Cell Biol* **19**, 5576-5587 (1999).
- 160 Gilles, C. *et al.* Transactivation of vimentin by beta-catenin in human breast cancer cells. *Cancer Res* **63**, 2658-2664 (2003).
- 161 Rivat, C. *et al.* Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. *FASEB J* **17**, 1721-1723, doi:10.1096/fj.03-0132fje03-0132fje [pii] (2003).
- 162 Huber, M. A. *et al.* NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. *J Clin Invest* **114**, 569-581, doi:10.1172/JCI21358 (2004).
- 163 Foubert, E., De Craene, B. & Berx, G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. *Breast Cancer Res.* **12**, 206.
- 164 Yori, J. L., Johnson, E., Zhou, G., Jain, M. K. & Keri, R. A. Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. *J Biol Chem* **285**, 16854-16863, doi:M110.114546 [pii]10.1074/jbc.M110.114546.
- 165 Liu, Y. N. *et al.* Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor beta-initiated prostate cancer epithelial-mesenchymal transition. *Mol Cell Biol* **32**, 941-953, doi:MCB.06306-11 [pii]10.1128/MCB.06306-11.
- 166 Kouros-Mehr, H. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. *Cancer Cell* **13**, 141-152 (2008).
- 167 Chakrabarti, R. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nature Cell Biol.* **14**, 1212-1222.
- 168 Elledge, S. J. & Amon, A. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. *Cancer Cell* **1**, 129-132 (2002).
- 169 Ramji, D. P. & Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. *Biochem J* **365**, 561-575, doi:10.1042/BJ20020508BJ20020508 [pii] (2002).
- 170 McKnight, S. L. McBindall--a better name for CCAAT/enhancer binding proteins? *Cell* **107**, 259-261, doi:S0092-8674(01)00543-8 [pii] (2001).
- 171 Begay, V., Smink, J. & Leutz, A. Essential requirement of CCAAT/enhancer binding proteins in embryogenesis. *Mol Cell Biol* **24**, 9744-9751, doi:24/22/9744 [pii]10.1128/MCB.24.22.9744-9751.2004 (2004).
- 172 Lopez, R. G. *et al.* C/EBPalpha and beta couple interfollicular keratinocyte proliferation arrest to commitment and terminal differentiation. *Nat Cell Biol* **11**, 1181-1190, doi:ncb1960 [pii]10.1038/ncb1960 (2009).
- 173 Descombes, P. & Schibler, U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. *Cell* **67**, 569-579, doi:0092-8674(91)90531-3 [pii] (1991).
- 174 Robinson, G. W., Johnson, P. F., Hennighausen, L. & Sterneck, E. The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. *Genes Dev* **12**, 1907-1916 (1998).
- 175 Sebastian, T., Malik, R., Thomas, S., Sage, J. & Johnson, P. F. C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. *EMBO J* **24**, 3301-3312 (2005).
- 176 Bundy, L. M. & Sealy, L. CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. *Oncogene* **22**, 869-883 (2003).
- 177 Zahnow, C. A. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. *Expert Rev Mol Med* **11**, e12 (2009).
- 178 Gomis, R. R., Alarcon, C., Nadal, C., Van Poznak, C. & Massague, J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. *Cancer Cell* **10**, 203-214 (2006).

- 179 Lam, E. W. F., Brosens, J. J., Gomes, A. R. & Koo, C.-Y. Forkhead box proteins: tuning forks for
transcriptional harmony. *Nat Rev Cancer* **13**, 482-495.
- 180 Carlsson, P. & Mahlapuu, M. Forkhead transcription factors: key players in development and
metabolism. *Dev Biol* **250**, 1-23, doi:S0012160602907803 [pii] (2002).
- 181 Takahashi, K., Liu, F. C., Hirokawa, K. & Takahashi, H. Expression of Foxp4 in the developing and
adult rat forebrain. *J Neurosci Res* **86**, 3106-3116, doi:10.1002/jnr.21770 (2008).
- 182 Li, S. *et al.* Foxp1/4 control epithelial cell fate during lung development and regeneration through
regulation of anterior gradient 2. *Development* **139**, 2500-2509, doi:dev.079699
[pii]10.1242/dev.079699.
- 183 Lu, M. M., Li, S., Yang, H. & Morrisey, E. E. Foxp4: a novel member of the Foxp subfamily of
winged-helix genes co-expressed with Foxp1 and Foxp2 in pulmonary and gut tissues. *Gene Expr
Patterns* **2**, 223-228, doi:S1567133X02000583 [pii] (2002).
- 184 Teufel, A., Wong, E. A., Mukhopadhyay, M., Malik, N. & Westphal, H. FoxP4, a novel forkhead
transcription factor. *Biochim Biophys Acta* **1627**, 147-152, doi:S0167478103000745 [pii] (2003).
- 185 Rouso, D. L. *et al.* Foxp-mediated suppression of N-cadherin regulates neuroepithelial character and
progenitor maintenance in the CNS. *Neuron* **74**, 314-330, doi:S0896-6273(12)00232-2
[pii]10.1016/j.neuron.2012.02.024.
- 186 Kouros-Mehr, H. *et al.* GATA-3 links tumor differentiation and dissemination in a luminal breast
cancer model. *Cancer Cell* **13**, 141-152, doi:S1535-6108(08)00008-1 [pii]10.1016/j.ccr.2008.01.011
(2008).
- 187 Howarth, K. D. *et al.* Array painting reveals a high frequency of balanced translocations in breast
cancer cell lines that break in cancer-relevant genes. *Oncogene* **27**, 3345-3359, doi:1210993
[pii]10.1038/sj.onc.1210993 (2008).
- 188 Takata, R. *et al.* Genome-wide association study identifies five new susceptibility loci for prostate
cancer in the Japanese population. *Nat Genet* **42**, 751-754, doi:ng.635 [pii]10.1038/ng.635.
- 189 Yap, A. S., Briehner, W. M. & Gumbiner, B. M. Molecular and functional analysis of cadherin-based
adherens junctions. *Annu Rev Cell Dev Biol* **13**, 119-146, doi:10.1146/annurev.cellbio.13.1.119 (1997).
- 190 Harhaj, N. S. & Antonetti, D. A. Regulation of tight junctions and loss of barrier function in
pathophysiology. *Int J Biochem Cell Biol* **36**, 1206-1237,
doi:10.1016/j.bioce.2003.08.007S1357272503002978 [pii] (2004).
- 191 Raschperger, E. *et al.* The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial
tight junctions, with a potential role in regulating permeability and tissue homeostasis. *Exp Cell Res*
312, 1566-1580, doi:S0014-4827(06)00023-1 [pii]10.1016/j.yexcr.2006.01.025 (2006).
- 192 Raschperger, E., Engstrom, U., Pettersson, R. F. & Fuxe, J. CLMP, a novel member of the CTX family
and a new component of epithelial tight junctions. *J Biol Chem* **279**, 796-804,
doi:10.1074/jbc.M308249200M308249200 [pii] (2004).
- 193 Ebnet, K. *et al.* The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion
molecule (JAM). *EMBO J* **20**, 3738-3748, doi:10.1093/emboj/20.14.3738 (2001).
- 194 Fanning, A. S. 265-284 (2001).
- 195 Chen, Y., Lu, Q., Schneeberger, E. E. & Goodenough, D. A. Restoration of tight junction structure and
barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed
Madin-Darby canine kidney cells. *Mol. Biol. Cell* **11**, 849-862 (2000).
- 196 Gonzalez-Mariscal, L., Chavez de Ramirez, B. & Cerejido, M. Tight junction formation in cultured
epithelial cells (MDCK). *J. Membr. Biol.* **86**, 113-125 (1985).
- 197 Benais-Pont, G., Matter, K. & Balda, M. S. 367-394 (2001).
- 198 Farquhar, M. G. & Palade, G. E. Junctional complexes in various epithelia. *J. Cell Biol.* **17**, 375-412
(1963).
- 199 Zahraoui, A., Louvard, D. & Galli, T. Tight junction, a platform for trafficking and signaling protein
complexes. *J. Cell Biol.* **151**, F31-36 (2000).

- 200 Ebnet, K., Schulz, C. U., Meyer Zu Brickwedde, M. K., Pendl, G. G. & Vestweber, D. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. *J. Biol. Chem.* **275**, 27979-27988 (2000).
- 201 Zahraoui, A., Louvard, D. & Galli, T. Tight junction, a platform for trafficking and signaling protein complexes. *J Cell Biol* **151**, F31-36 (2000).
- 202 Betanzos, A. *et al.* The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. *Exp Cell Res* **292**, 51-66, doi:S0014482703004518 [pii] (2004).
- 203 Matter, K. & Balda, M. S. Signalling to and from tight junctions. *Nat Rev Mol Cell Biol* **4**, 225-237 (2003).
- 204 Philipson, L. & Pettersson, R. F. The coxsackie-adenovirus receptor—a new receptor in the immunoglobulin family involved in cell adhesion. *Curr. Top. Microbiol. Immunol.* **273**, 87-111 (2004).
- 205 Raschperger, E. The coxsackie- and adenovirus receptor (CAR) is an *in vivo* marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. *Exp. Cell Res.* **312**, 1566-1580 (2006).
- 206 Coyne, C. B. & Bergelson, J. M. CAR: a virus receptor within the tight junction. *Adv. Drug Deliv. Rev.* **57**, 869-882 (2005).
- 207 Asher, D. R. *et al.* Coxsackievirus and adenovirus receptor is essential for cardiomyocyte development. *Genesis* **42**, 77-85, doi:10.1002/gene.20127 (2005).
- 208 Pazirandeh, A. *et al.* Multiple phenotypes in adult mice following inactivation of the Coxsackievirus and Adenovirus Receptor (Car) gene. *PLoS ONE* **6**, e20203, doi:10.1371/journal.pone.0020203PONE-D-11-00711 [pii].
- 209 Vincent, T. *et al.* A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF- β mediated epithelial-mesenchymal transition. *Nat Cell Biol* **11**, 943-950 (2009).
- 210 Goodman, L. S., Wintrobe, M. M. & *et al.* Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. *J Am Med Assoc* **132**, 126-132 (1946).
- 211 Teicher, B. A. Tumor resistance to alkylating agents conferred by mechanisms operative only *in vivo*. *Science* **247**, 1457-1461 (1990).
- 212 Kamrava, M., Bernstein, M. B., Camphausen, K. & Hodge, J. W. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? *Mol. Biosyst.* **5**, 1262-1270 (2009).
- 213 Haber, D. A., Gray, N. S. & Baselga, J. The evolving war on cancer. *Cell* **145**, 19-24.
- 214 Aabo, K. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. *Br. J. Cancer* **78**, 1479-1487 (1998).
- 215 Gore, M. E., Fryatt, I., Wiltshaw, E. & Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. *Gynecol. Oncol.* **36**, 207-211 (1990).
- 216 ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet* **360**, 505-515 (2002).
- 217 Sun, J. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. *Cancer Res.* **59**, 4919-4926 (1999).
- 218 Perez, R. P. Cellular and molecular determinants of cisplatin resistance. *Eur. J. Cancer* **34**, 1535-1542 (1998).
- 219 Niedner, H., Christen, R., Lin, X., Kondo, A. & Howell, S. B. Identification of genes that mediate sensitivity to cisplatin. *Mol. Pharmacol.* **60**, 1153-1160 (2001).

- 220 Dawood, S. *et al.* Survival among women with triple receptor-negative breast cancer and brain metastases. *Ann Oncol* **20**, 621-627, doi:mdn682 [pii]10.1093/annonc/mdn682 (2009).
- 221 Cicin, I. *et al.* Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. *Med Oncol* **26**, 335-343, doi:10.1007/s12032-008-9126-3 (2009).
- 222 Kotiyal, S. & Bhattacharya, S. Breast cancer stem cells, EMT and therapeutic targets. *Biochem Biophys Res Commun* **453**, 112-116, doi:S0006-291X(14)01695-7 [pii] 10.1016/j.bbrc.2014.09.069.
- 223 Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. *Ann. Surg.* **175**, 409-416 (1972).
- 224 Dougan, M. & Dranoff, G. Immune therapy for cancer. *Annu. Rev. Immunol.* **27**, 83-117 (2009).
- 225 Tozer, G. M., Kanthou, C. & Baguley, B. C. Disrupting tumour blood vessels. *Nat Rev Cancer* **5**, 423-435 (2005).
- 226 Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704-715, doi:S0092-8674(08)00444-3 [pii]10.1016/j.cell.2008.03.027 (2008).
- 227 He, M., Xu, Z., Ding, T., Kuang, D. M. & Zheng, L. MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. *Cell Mol Immunol* **6**, 343-352 (2009).
- 228 Costinean, S. *et al.* Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. *Blood* **114**, 1374-1382 (2009).
- 229 Marsolier, J. *et al.* OncomiR addiction is generated by a miR-155 feedback loop in Theileria-transformed leukocytes. *PLoS Pathog* **9**, e1003222, doi:10.1371/journal.ppat.1003222PPATHOGENS-D-12-02103 [pii].
- 230 Excoffon, K. J., Hruska-Hageman, A., Klotz, M., Traver, G. L. & Zabner, J. A role for the PDZ-binding domain of the coxsackie B virus and adenovirus receptor (CAR) in cell adhesion and growth. *J Cell Sci* **117**, 4401-4409, doi:10.1242/jcs.01300jcs.01300 [pii] (2004).
- 231 Kolawole, A. O. *et al.* The PDZ1 and PDZ3 domains of MAGI-1 regulate the eight-exon isoform of the coxsackievirus and adenovirus receptor. *J Virol* **86**, 9244-9254, doi:JVI.01138-12 [pii]10.1128/JVI.01138-12.